Stockwinners Market Radar for September 03, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:31 EDT Southwest discloses 100% completion factor on Labor Day - The company states: "Southwest Airlines closed out summer travel with zero cancellations on Labor Day, highlighting yet another reliable operation during the airline's peak season. Southwest Employees delivered world-class Hospitality by connecting more than 1.8 million Customers to what's important in their lives during the final summer travel weekend. On more than 14,500 scheduled flights, Southwest achieved a 99.9 percent completion factor to lead the industry in domestic flight completion coming out of the Labor Day holiday. For the entire summer travel period2, the airline carried a record number of more than 54 million Customers across more than 414,000 flights. Ontime performance improved by two percentage points compared with 2023, along with a 99.3% completion factor."

20:12 EDT Cathie Wood's ARK Investment bought 186K shares of Intellia Therapeutics today

18:22 EDT Business First Bancshares gets regulatory approval for Oakwood Bancshares merger - Business First Bancshares announced it has received all required regulatory approvals and non-objections to complete its merger with Oakwood Bancshares, Inc., the holding company for Oakwood Bank, a Texas banking association. On August 27, 2024, Oakwood's shareholders voted to approve the merger. Upon completion, it is expected that b1BANK's assets will increase to approximately $7.6 billion, with over $5.9 billion in consolidated total loans. This will also add four full-service banking centers to b1BANK's footprint in the Dallas-Fort Worth metropolitan area, as well as one branch in each of Snyder and Oakwood, Texas. Roy J. Salley, chairman and chief executive officer of Oakwood Bank, will join b1BANK as regional chairman, Dallas, and William G. Hall, chairman of Oakwood Bancshares, Inc., will be appointed to the boards of directors of Business First and b1BANK.

18:01 EDT Cemex acquires majority stake in RC-Baustoffe Berlin recycling company - Cemex announced that it has acquired a majority stake in RC-Baustoffe Berlin GmbH & Co., a recycling company and part of the Heim Group, as part of its ongoing efforts to grow its circularity business. The Berlin-based company processes mineral construction, demolition, and excavation materials. This acquisition will integrate with Regenera, Cemex's business that provides circularity solutions to extend the life cycle of construction products and materials through reuse in value-added products. The acquired recycling facility can process up to 400,000 tons of material per year, which Regenera will turn into repurposed aggregates for concrete production, reintroducing them into the construction value chain. In addition to its recycling capabilities, RC-Baustoffe Berlin operates the first plant to permanently store biogenic CO2 in recycled mineral waste in Germany. Regenera recovered over 9 million tons of CDEM in 2023 and has an objective of recovering over 14 million tons annually by 2030.

17:13 EDT Northrop Grumman awarded $197.5M U.S. Navy contract - Northrop Grumman Defense Systems, Rocket Center, West Virginia, is awarded a $197,516,776 firm-fixed-price, indefinite-delivery/indefinite-quantity contract for the full rate production of 56,000 FMU-139D/B Bomb Tactical Electronic Fuze systems. Additionally, this contract procures 500 FMU-139D/B Fuze, accessory kits; 50 FMU-139D(D-1)/B Fuze system inserts; 2,000 FMU-139D(D-2)/B inert load crew training Fuze systems; 50 FMU-139D(D-5)/B inert cut away Fuzes; 100 FZU-48A/B bomb initiators; 100 power cables; and 100 closure rings; as well as associated non-recurring engineering, data and first article testing in support of the Joint Direct Attack Mission family of weapons for the Navy, Air Force, and Foreign Military Sales customers. Work will be performed in Rocket Center, West Virginia (91.09%); Plymouth, Minnesota (7.54%); and Camden, Arkansas (1.37%), and is expected to be completed in December 2029.

17:09 EDT Ascendis Pharma, Royalty Pharma enter $150M royalty funding deal - The company states: "Ascendis Pharma A/S (ASND) and Royalty Pharma plc (RPRX) announced that Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S, has entered into a $150 million capped synthetic royalty funding agreement with Royalty Pharma based on U.S. net sales of YORVIPATH. Under the terms of the agreement, Ascendis receives an upfront payment of $150 million in exchange for a 3% royalty on U.S. net sales of YORVIPATH. The royalty payments to Royalty Pharma will cease upon reaching a multiple of 2.0x, or 1.65x if Royalty Pharma receives royalties in that amount by December 31, 2029." "We are pleased to again partner with Royalty Pharma, a leading funder of innovation across the biopharma industry, as we launch YORVIPATH in the U.S. as the first and only FDA approved treatment of hypoparathyroidism in adults," said Jan Mikkelsen, CEO "This transaction reflects the significant value of YORVIPATH and our commitment to reduce our cost of capital while maintaining flexibility to support our global commercial capabilities."

16:57 EDT S&P Global Ratings to pay $20M to resolve SEC investigation - As part of an industry-wide investigation into off-channel communications by the U.S Securities and Exchange Commission, S&P Global Ratings, a division of S&P Global, and certain other nationally recognized statistical rating organizations, reached a settlement to resolve violations of recordkeeping rules. The matter was previously disclosed by S&P Global in its public filings. SPGR agreed to pay a penalty of $20M as part of the resolution. In the SEC's order, the SEC recognized SPGR's remedial acts and its cooperation with the SEC staff.

16:38 EDT Zscaler down 10% after Q4 results, FY25 guidance

16:38 EDT Zscaler reports change in non-GAAP measures presentation - The company said: "Effective August 1, 2024, the beginning of Zscaler's fiscal year ending July 31, 2025, we are using a long-term projected non-GAAP tax rate of 23% for the purpose of determining our non-GAAP net income and non-GAAP net income per share to provide better consistency across interim reporting periods in fiscal 2025 and beyond. Given the significant growth of our business and non-GAAP operating income, we believe this change is necessary to better reflect the performance of our business. We have included a table in this earnings release illustrating the impact of this change to these non-GAAP financial measures to all periods presented. We will continue to assess the appropriate non-GAAP tax rate on a regular basis, which could be subject to change for a variety of reasons, including the rapidly evolving global tax environment, significant changes in our geographic earnings mix, or other changes to our strategy or business operations."

16:33 EDT BrightSpring Health completes acquisition of Haven Hospice - BrightSpring Health Services announced that it completed the acquisition of the assets of North Central Florida Hospice and Haven Medical Group, a Florida-based company holding a Certificate of Need for comprehensive hospice care services in 18 counties in north central Florida, effective September 1, 2024. BrightSpring's acquisition of Haven allows the company to provide advance care planning, palliative, and hospice services throughout Florida Agency for Health Care Administration service areas 3A, 4A, and 4B. Total consideration for the acquisition is $60M, with $15M in cash paid on September 1, $30M in company equity granted on September 1, and an additional $15M in a seller note payable on September 1, 2028.

16:31 EDT Phillips Edison increases monthly dividend distribution by 5.1% to 10.25c p/s - Phillips Edison & Company announced that its Board of Directors approved a 5.1% increase to the monthly dividend distributions payable October 1, and November 1, to common stockholders of record as of September 16 and October 15 respectively. The Board approved the distribution at a rate of 10.25c per share of the Company's common stock. When annualized, this is equal to a rate of $1.23 per share, representing an increase of 5.1% over the previous annualized rate of $1.17 per share. Operating partnership unit holders receive distributions at the same rate as common stockholders, subject to the required tax withholding. Jeff Edison, Chairman and Chief Executive Officer of PECO stated: "The continued strength of our operating performance and growth of our cash flows allow us to increase our monthly dividend distribution once again. This increase is attributed to the success of our differentiated and focused strategy of owning right-sized, high-quality, grocery-anchored neighborhood shopping centers, the PECO team's ability to drive results at the property level and the many advantages of the suburban markets where we operate our centers. The PECO team is well positioned to continue to deliver solid earnings growth, market-leading operating metrics and long-term value creation."

16:30 EDT Curtiss-Wright awarded $26M contract by Belgian Air Force - Curtiss-Wright announced that it has been awarded a $26M multi-year contract by the Belgian Air Force to implement a modernization program for its aircraft arresting systems. Under the agreement, Curtiss-Wright will provide new cable systems and related turnkey services to three airbases to support the upcoming delivery of the F-35 to Belgium, as well as safeguard its emergency takeoff and landing phases. The contract also provides various services, spares, repair, and overhaul supporting the Belgian Air Force's military flight operations.

16:26 EDT Clover Health unit Counterpart in deal with Iowa Clinic to deploy AI technology - Counterpart Health announced a multi-year agreement with The Iowa Clinic, P.C., one of the most highly regarded multispecialty healthcare groups in the United States. This deal positions The Iowa Clinic as one of Counterpart's anchor customers in the Midwest, as Counterpart drives a broader strategic expansion across the country. Counterpart is a subsidiary of Clover Health Investments...Under the terms of the agreement, clinicians serving The Iowa Clinic's Medicare Advantage and Medicare Shared Savings Program patients will use Counterpart Assistant, Counterpart Health's cutting-edge cloud-based software platform. Additionally, the platform will be made available to The Iowa Clinic's clinically integrated network partners throughout the Midwest. Counterpart will receive a per-member, per-month fee, as well as potential incentive payments contingent on achieving certain care management goals.

16:24 EDT Metagenomi announces data from hemophilia study supporting MGX-001 - Metagenomi announced data from an ongoing preclinical study designed to provide evidence supporting the potential durability and safety of the company's hemophilia A gene editing investigational therapy, MGX-001. "We are thrilled to achieve this preclinical milestone supporting our recent decision to declare MGX-001 as our development candidate for hemophilia A," said Brian C. Thomas, PhD, CEO and founder of Metagenomi. "We conducted this NHP study in response to a competitive landscape where gene therapies have been unable to achieve long term persistence of FVIII activity levels in patients. Establishing proof-of-concept of site specific gene integration and durable activity levels of FVIII in NHPs over twelve months in hemophilia A represents an important validation of our platform. Our goal for MGX-001 is to provide a one-time, curative treatment for adults and children with hemophilia A. Furthermore, we intend to leverage the MGX-001 editing platform to pursue additional therapies for secreted protein disorders."..."The treatment of hemophilia, which has undergone many transformative changes over the past 60 years, is poised for yet another disruptive change: the use of genome editing, with site specific integration of FVIII, to produce functional cures in patients with hemophilia A. I am encouraged by the preclinical progress in the genome editing space to potentially provide a new path to a one-time, curative treatment option for both adults and children in hemophilia A in the future," said Dr. Glenn Pierce, member of the Metagenomi Scientific Advisory Board.

16:16 EDT AMD apppints Keith Strier senior VP of global AI markets - AMD (AMD) announced that Keith Strier has joined the company as senior VP of global AI markets. Strier has more than 30 years of experience in strategic business and market development, technical engineering and enabling responsible AI deployments. He most recently served as VP of worldwide AI initiatives at NVIDIA (NVDA), with responsibility for expanding commercial engagements with foreign governments. At AMD, he will be responsible for expanding the company's AI vision, driving new ecosystem capabilities and accelerating strategic AI engagements globally across public and private sectors. He reports to AMD executive VP and Chief Technology Officer, Mark Papermaster. "Keith is an excellent addition to our leadership team, bringing deep market expertise and extensive network of relationships that will significantly strengthen our AI engagements globally," said AMD CEO, Dr. Lisa Su. "His extensive experience and proven track record acting as a trusted advisor to countries and companies uniquely positions him to help accelerate adoption of AMD-powered solutions to meet the growing demand for AI."

16:14 EDT INNOVATE Corp. regains compliance with NYSE minimum price requirement - INNOVATE Corp. announced that it has received a letter from the NYSE dated August 27, notifying the company that it is no longer considered below the NYSE's continued listing criterion of a minimum average share price of $1.00 over a 30 trading-day period.

16:11 EDT Accuray CEO Suzanne Winter to take temporary medical leave of absence - Accuray announced that President and CEO Suzanne Winter will be taking a temporary medical leave of absence to receive care for a treatable form of cancer, effective immediately. Accuray Senior Vice President and Chief Commercial Officer Sandeep Chalke will serve as the interim CEO during Winter's absence. To ensure that Chalke and the organization have the necessary support, the company has formed an Executive Committee of the Board of Directors, consisting of Joseph Whitters, Chairman of the Accuray Board, and Anne Le Grand, Chair of the Science and Technology Committee, that will advise Chalke in his interim capacity.

16:09 EDT Asana names Sonalee Parekh as new CFO - Asana (ASAN) announced the appointment of Sonalee Parekh as Chief Financial Officer, effective September 11, 2024. Parekh will succeed Tim Wan, who has served in the role since 2017. Wan will remain with the company in an advisory position to support the transition. Parekh brings more than 25 years of experience in the technology and banking sectors to Asana, having previously held executive finance roles at leading public companies including Chief Financial Officer at RingCentral (RNG) and Divisional CFO, Head of Corporate Development and Investor Relations at Hewlett Packard Enterprise (HPE). Dustin Moskovitz, Asana's co-founder and CEO, welcomed Parekh to the leadership team: "Sonalee's public company experience and market perspective, coupled with her proven track record of driving growth and profitability at scale, makes her the ideal person to partner with me and the leadership team as we execute on the large opportunity ahead of us. She's had a front-row seat to some of the most transformative technology trends and we're in the midst of another pivotal moment. AI has the enormous potential to reshape not only the work management category, but the entire software industry. Sonalee's experience overseeing and fostering efficient growth during critical inflection points will be invaluable to Asana."

16:06 EDT Caribou Biosciences CFO Jason O'Byrne resigns - In a regulatory filing, the company disclosed that on September 1, Jason O'Byrne, CFO of Caribou Biosciences, informed the company of his intent to resign from his position, effective September 27, to pursue another opportunity. O'Byrne's resignation is not the result of any disagreement with the company on any matter related to the company's financial reporting or accounting policies, procedures, estimates, or judgments. The company has initiated a search for a new CFO. The company intends to appoint Ryan Fischesser, the company's current VP of Finance and Controller, to assume the role of the company's principal accounting officer, effective as of the close of business on September 27. Fischesser had previously served as the company's principal accounting officer from the time of the company's initial public offering through December 15, 2022.

16:00 EDT Athira Pharma trading halted, news pending

14:22 EDT Qilian International Holding Group Ltd trading halted, volatility trading pause

13:13 EDT Comstock says AFR report contains 'material false and misleading statements' - In a regulatory filing, Comstock Inc. disclosed that on September 3, the company became aware of an article entitled "US outfit seeks $3.7bn to power up Australia's green aviation fuel sector," written by Sarah Thompson, Kanika Sood and Emma Rapaport and published online by Australian Financial Review, or AFR. "The Article contains several material false and misleading statements, including, among other statements: the proposed capital raise by a subsidiary of the Company; the existence of an exclusive Asia Pacific license; desired or preferred sites for refinery or other business operations; capital expenditure requirements; raw material tonnage; and forecasted revenues or earnings. Neither the Company nor any person acting on behalf of the Company contributed any of the content of the Article or had any communications with the Authors or the Publisher prior to the publication of the Article. The Company immediately contacted the Authors and the Publisher to demand that the Article be fully retracted," the filing stated.

12:55 EDT Comstock Mining trading halted, news pending

12:06 EDT Vicor responds to allegations made in securities litigation - Vicor Corporation disclosed facts that formed the basis for forward-looking statements about an expected revenue ramp, made in the company's July 25, 2023 Earnings Call, that were alleged to be untrue in recently-filed securities litigation against the company. These statements were true when made on the basis of the facts outlined below, Vicor said in a statement. "As of July 25, 2023, the company had booked over $30M in Non-Cancellable, Non-Returnable orders from a significant customer reflecting what the Company understood to be the Customer's allocation for a new program to the Company. Subsequent to the July 25, 2023 Earnings Call while continuing to honor the NCNR Orders, the Customer changed its allocation for the New Program, as the Company indicated in its forward-looking statements made in subsequent Earnings Calls. Accordingly, the Company's statements on July 25, 2023 were truthful and properly represented its reasonable expectations at the time."

12:04 EDT Rite Aid names Matt Schroeder as CEO - Rite Aid Corporation announced that Matt Schroeder has been appointed CEO after the company's emergence from Chapter 11. Schroeder joined Rite Aid in 2000 and most recently served as the company's CFO. He succeeds Jeffrey S. Stein, who has stepped down as CEO and Chief Restructuring Officer in connection with the company's emergence from Chapter 11. "Matt has served in various leadership positions during his tenure at Rite Aid and has a deep understanding of all aspects of our business," said Bruce Bodaken, Chair of Rite Aid's Board of Directors during its Chapter 11 process. "He has shown outstanding leadership through this process and is an excellent fit for the Company as it advances as a stronger organization."

12:00 EDT Direxion Daily Semiconductor Bull 3X Shares falls -16.8% - Direxion Daily Semiconductor Bull 3X Shares is down -16.8%, or -$6.50 to $32.29.

12:00 EDT Direxion Daily Junior Gold Miners Index Bear 3x Shares rises 10.2% - Direxion Daily Junior Gold Miners Index Bear 3x Shares is up 10.2%, or $3.19 to $34.52.

12:00 EDT Sable Offshore rises 37.8% - Sable Offshore is up 37.8%, or $6.36 to $23.20.

11:33 EDT Auna appoints Laurent Massart as EVP, strategy and equity capital markets - Auna announced the appointment of Laurent "Lorenzo" Massart as Executive Vice President, Strategy and Equity Capital Markets to its executive team. In this new role, the Investor Relations function will now report to Lorenzo and thus he will ensure Auna has a cohesive approach to communicating with our investors and stakeholders.

11:27 EDT BJ's Restaurants appoints Lyle Tick as President and Chief Concept Officer - BJ's Restaurants announced that Lyle Tick, former Brand President of Buffalo Wild Wings, will be appointed President and Chief Concept Officer, effective September 9. Tick has served as President and Chief Executive Officer of On the Border Mexican Grill & Cantina since December 2023. Interim Chief Executive Officer C. Bradford Richmond commented, "We are delighted to welcome Lyle to the BJ's team. Lyle has a history of leading iconic brands to unlock new chapters of growth and drive consumer relevance. Lyle's strategic customer focus and passion for brand clarity will enable BJ's to enhance its relevance and awareness. In addition to his experience and affinity for the casual dining space, Lyle's extensive experience with consumer goods and spirit brands will bring a fresh perspective to our marketing, innovation, culinary, beverage and brewing teams. I believe he will be a great addition and complement to our leadership team."

11:03 EDT Cleveland Browns' stadium to be called 'Huntington Bank Field' under new deal - The Cleveland Browns and The Huntington National Bank announced a 20-year partnership that includes the naming rights to the Browns' stadium, which will now be called "Huntington Bank Field." The bank stated: "As part of the new partnership, Huntington Bank, a super-regional bank headquartered in Columbus, Ohio, will also become the team's official and exclusive banking partner. The partnership strengthens both organizations' shared vision and long-standing commitment to the Cleveland community and broader region." Steve Steinour, Huntington Bank chairman, president and CEO, added: "Huntington Bank is thrilled to create this partnership and make this investment in the Cleveland Browns and Northeast Ohio. This is also a pivotal moment for us as it gives us a high-profile platform to elevate our brand nationally."

10:35 EDT Tilray completes acquisition of craft beer brands from Molson Coors - Tilray Brands (TLRY) completed the previously announced acquisition of craft breweries Hop Valley Brewing Company, Terrapin Beer Co., and Revolver Brewing, from Molson Coors Beverage Company (TAP). The company said, "This acquisition further strengthens Tilray's leadership position in the U.S. craft beer market as the 5th largest craft brewer in the country and the top craft brewer in the Pacific Northwest and Georgia. It also anchors Tilray in Texas, the second largest beer consumption state, and expands Tilray's craft beer portfolio across key beer markets, adding 30% new beer buying accounts."

10:33 EDT Concord Acquisition Corp II considering alternative listing with Nasdaq - Concord Acquisition Corp II has received notification from NYSE American indicating that the staff of NYSE has determined to initiate proceedings which may delist the Company's Class A Common Stock, Units, and Warrants. This step, anticipated as part of the Company's strategic journey to the public markets, is due to the Company not completing a business combination within 36 months as required by Sections 119(b) and 119(f) of the NYSE American Listed Company Guide. The Company has the right to request a review of this delisting determination by the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange. In line with its strategic plans, the Company intends to pursue this review and will seek to list its Securities on the OTC Markets for trading during the suspension on NYSE American. This transition is expected to be temporary as the Company remains hopeful that its appeal for an extension will be granted by the NYSE American. Simultaneously, the Company and its sponsor are actively exploring a listing on the Nasdaq. Concord remains focused on the public process, continuing to work diligently to achieve its listing goals and enhance shareholder value.

10:08 EDT Li-FT Power terminates Shorty West mineral property purchase agreement - LIFT announces that at the request of Infinity Stone Ventures Corp., it has terminated the mineral property purchase agreement dated July 17, 2024 regarding the Shorty West Lithium mineral claim. In connection with the termination, beneficial ownership of the Claim, which is adjacent to the Company's Yellowknife Lithium Project, was transferred to an arm's length private entity. The Company has now entered into a mineral property purchase agreement dated August [16] 2024 with that entity to acquire the Claim in consideration of the issuance 12,000 common shares, which is the same consideration which was offered to Infinity Stone. The shares, once issued, will be subject to applicable resale restrictions under Canadian securities laws. The completion of the acquisition is subject to the approval of the TSX Venture Exchange. No finder's fees are payable in connection with the acquisition.

10:06 EDT US Signal completes acquisition of OneNeck - US Signal Company has completed its acquisition of OneNeck IT Solutions and OneNeck Data Center Holdings from Telephone and Data Systems. Headquartered in Madison, Wisconsin, OneNeck provides secure hybrid IT and multi-cloud solutions through data centers in six Western and Midwestern states. Serving more than 1,000 customers across 45 states, OneNeck caters to sectors including banking, education, engineering, food and beverage, government, healthcare, manufacturing, and retail. Grand Rapids, Michigan-based US Signal provides data center colocation, connectivity, cloud hosting, data protection, and disaster recovery services to regional enterprise customers and large national telecommunications carriers. It operates a 9,500-route mile fiber network and has 10 data centers across Michigan, Illinois, Indiana and Wisconsin. The acquisition: Increases the number of US Signal data centers from 10 to 16, quadrupling square footage; Extends US Signal's footprint to the West Coast with the addition of Phoenix, Arizona; Denver, Colorado; and Bend, Oregon data centers; Adds OneNeck's Madison, Wisconsin; Minneapolis, Minnesota; and Des Moines, Iowa markets to US Signal's fiber network, and More than triples commercial power under management.

10:01 EDT Ferguson, ServiceTitan enter strategic collaboration - ServiceTitan announced the launch of its strategic collaboration with Ferguson. With this strategic collaboration, Ferguson's contractor network can leverage ServiceTitan's powerful residential, commercial, HVAC, and construction platform, enabling them to win more business, increase profitability, and maximize the lifetime value of their downstream customers.

10:00 EDT Direxion Daily Semiconductor Bull 3X Shares falls -9.9% - Direxion Daily Semiconductor Bull 3X Shares is down -9.9%, or -$3.84 to $34.95.

10:00 EDT Direxion Daily Semiconductor Bear 3X Shares rises 10.0% - Direxion Daily Semiconductor Bear 3X Shares is up 10.0%, or $2.21 to $24.28.

10:00 EDT Sable Offshore rises 26.2% - Sable Offshore is up 26.2%, or $4.41 to $21.25.

09:55 EDT Avalo Therapeutics trading resumes

09:48 EDT Unity rises 10.4% - Unity is up 10.4%, or $1.70 to $18.07.

09:47 EDT VeriSign Inc falls -6.7% - VeriSign Inc is down -6.7%, or -$7.88 to $110.49.

09:47 EDT Owlet announces expanded availability of Dream Sock across Europe - Owlet announced that the medically-certified Dream Sock will soon be available in even more countries, including Poland, Greece, and the Czech Republic. Dream Sock is the Company's medically-certified baby monitor accessible across Europe, giving parents safe and accurate health readings and actionable alarms while their baby sleeps. Dream Sock is available now for purchase in the UK and select European markets. Dream Sock will be available in the following markets via Owlet's localized websites and key retailers in the coming weeks: Poland, the Czech Republic, Slovakia, Hungary, Romania, Bulgaria, and Greece

09:45 EDT Avalo Therapeutics trading halted, volatility trading pause

09:42 EDT Anaergia selected to design, build biogas facility in South Korea - Anaergia's subsidiary, Anaergia Singapore, has received a Letter of Award from New Jeju Bio to design and build the Jeju Bio Energy Biogas Plant, to be constructed in Jeju Island, South Korea. Based on the initial specifications, the Award is for an amount of approximately C$25 million, and it is subject to a number of routine conditions, including the client obtaining final financing for the project. The Facility is expected to convert approximately 50,000 tons per year of organic waste into two megawatts of energy. The feedstock is anticipated to include various waste streams generated by slaughterhouses, citrus juice facilities and food production facilities on Jeju Island. These solid and liquid feedstocks are intended be digested anaerobically, and the biogas produced from this process is expected to be utilized in a biogas combined heat and power unit. The Facility is to include pretreatment technologies, and Anaergia's Omnivore anaerobic digestion system to produce approximately two megawatts of renewable energy and heat to be utilized for digestion, pasteurization and evaporation. The Facility also is intended to generate digestate that is intended to be composted into fertilizer at an offsite location. The wastewater from the Facility is expected to be treated and recycled for use at the Facility and off-site agricultural use. The Facility is expected to significantly reduce greenhouse gas emissions from the island of Jeju while recycling its waste. South Korea has announced a national biogas strategy that aims to produce up to 500 million Nm/yr of biogas by 2026, which would cut GHG emissions by one million tonnes per year.

09:32 EDT Kingstone Companies reduces debt by 25%, extends maturity to June 2026 - Kingstone Companies has entered into a new Note Exchange Agreement with its existing noteholders to refinance its outstanding 12% Senior Notes in the aggregate principal amount of $19.95 million due on December 30, 2024. Pursuant to the Exchange Agreement, Kingstone will issue to the noteholders, in exchange for their Existing Notes, new 13.75% Senior Notes due June 30, 2026, in the aggregate principal amount of $14.95 million along with cash totaling $5 million. In addition, the expiration date for the warrants issued in 2022 at the time of the issuance of the Existing Notes will be extended to June 30, 2026. The exchange is scheduled to close on Thursday, September 12, 2024.

09:30 EDT Lexaria Bioscience enters material transfer agreement for DehydraTECH research - Lexaria Bioscience has entered into a Material Transfer Agreement with a pharmaceutical company to evaluate Lexaria's DehydraTECH technology in a pre-clinical setting. Under the terms of the agreement, Lexaria is responsible for formulation and supply of certain DehydraTECH compositions. The pharmacokinetics of DehydraTECH compositions will be evaluated in animal studies. Lexaria has awarded to PharmaCO a temporary exclusive license option limited to specific DehydraTECH concepts and formulations under examination. The work should be complete within roughly 6 months or less.

09:29 EDT SAP Chief Technology Officer Muller to leave company effective September 30 - SAP SE announced that the SAP Supervisory Board has reached a mutual agreement with Chief Technology Officer and Executive Board Member Dr.-Ing. Jurgen Muller to leave the company's Executive Board, effective September 30, 2024. Muller stated: "I want to address an incident at a past company event where my behavior was inappropriate. I regret being inconsiderate and sincerely apologize to everyone affected. I recognize my behavior at that moment did not reflect our values at SAP. I take full responsibility and believe stepping down is best for the company. I wish the team continued success."

09:27 EDT Moderna receives MHRA authorization for updated COVID-19 vaccine - Moderna announced that the Medicines and Healthcare products Regulatory Agency has authorized its updated COVID-19 vaccine targeting the JN.1 variant of SARS-CoV-2. Following the MHRA decision, doses will be available for eligible groups as part of the NHS autumn vaccination program, which is prioritized for use in people at greatest risk of serious illness from COVID-19. For the first time in the UK, the updated vaccine, Spikevax JN.1, will also be available to purchase privately for those who are not eligible for the NHS Autumn vaccination program. The updated vaccine will be available from high street pharmacies, occupational health providers, and private healthcare companies. The approval follows guidance from the World Health Organization Technical Advisory Group on COVID-19 Vaccine Composition, which recommended that COVID-19 vaccines be updated to target the JN.1 family of Omicron subvariants for the 2024/25 vaccination campaign. At present, the JN.1 group of subvariants remain dominant in the UK.

09:27 EDT Aaron's down 1% after J Capital Research questions deal in short report

09:24 EDT PaxMedica secures immediate exercise of warrants - PaxMedica announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,423,080 shares of common stock of the originally issued in November 2023, having an exercise price of 1.30 per share, at a reduced exercise price of $0.20 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1. The offering is expected to close on or about September 4, 2024, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase up to 8,846,160 shares of common stock. The new warrants will have an exercise price of $0.20 per share, will be immediately exercisable upon issuance and will have a term of five years from the issuance date. The gross proceeds to the Company from the exercise of the warrants are expected to be $884,616, prior to deducting placement agent fees and estimated offering expenses. The Company intends to use the net proceeds from the offering for the continuing development of PAX-101, working capital, and general corporate purposes.

09:23 EDT Perficient announces multi-year partnership with NFL's Atlanta Falcons - Perficient announced a multi-year partnership with the National Football League's, NFL, Atlanta Falcons, expanding its relationship with AMB Sports and Entertainment, AMBSE. This partnership builds on Perficient's ongoing collaboration with Major League Soccer's, MLS, Atlanta United and extends their digital transformation expertise to both teams.

09:22 EDT Valneva, Pfizer say Phase 2 Lyme disease vaccine study positive - Valneva (VALN) and Pfizer (PFE) announced "positive" immunogenicity and safety data from their VLA15-221 Phase 2 study following a second booster vaccination of their Lyme disease vaccine candidate, VLA15, given one year after receiving the first booster dose. The immune response and safety profile of VLA15 one month after receiving the second booster dose were similar to those reported after receiving the first booster dose, showing compatibility with the anticipated benefit of a booster vaccination prior to each Lyme season, the companies said in a statement. "These latest results from the VLA15-221 Phase 2 study again demonstrated a significant anamnestic antibody response across all six serotypes covered by the vaccine candidate in pediatric (5 to 11 years of age) and adolescent (12 to 17 years of age) participants, as well as in adults (18 to 65 years of age), measured one month after administration of this second booster dose (month 31). A high proportion of participants seroconverted after the second booster dose, yielding seroconversion rates above 90% for all outer surface protein A serotypes in all age groups, in-line with SCRs after the first booster. Geometric Mean Titers at one month post first and second booster (i.e. month 19 vs. month 31) were comparably high," they added.

09:21 EDT Limbach Holding acquires Kent Island Mechanical - Limbach Holdings announced that it has acquired Kent Island Mechanical for an initial purchase price of $15M. Based in Laurel, Maryland and serving the Greater Washington, D.C. metro region, KIM is a leading service provider to facility owners who require solutions for maintaining complex building systems. Transaction Highlights: The acquisition expands Limbach's design, engineering, maintenance, capital project, and emergency mechanical solutions capabilities. KIM's workforce, business model, and customer base complement and bolster Limbach's existing Mid-Atlantic business and aligns with the Company's strategy to expand Owner Direct Relationships with owners of mission-critical facilities in core end-markets. Limbach's current expectation is that KIM will contribute approximately $30 million in revenue and over $4 million in EBITDA annually beginning in 2025. Total consideration paid by Limbach at closing was $15 million. The acquisition will be funded from available cash and has performance-based, contingent earn-outs totaling $5 million, which would potentially be payable over the next two years.

09:20 EDT Masco enters definitive agreement to sell Kichler Lighting for $125M - Masco Corporation announced that it has signed a definitive agreement to sell its Kichler Lighting business to an affiliate of Kingswood Capital Management for a purchase price of approximately $125M, subject to customary adjustments. "Under Masco's ownership, Kichler has undergone a series of transformations which have generated efficiencies within its business, improved customer service, and enabled greater product innovation. Going forward, we believe this business has greater potential to realize future growth as part of an organization with a more concerted focus on lighting," said Keith Allman, President and CEO, Masco Corporation. "We are confident this transaction will be mutually beneficial to Kichler Lighting and Kingswood Capital Management, while simultaneously driving greater value for Masco shareholders."

09:19 EDT Masimo urges stockholder to vote 'FOR' only the company's director nominees - Masimo mailed a letter to stockholders in connection with its upcoming Annual Meeting of Stockholders to be held on September 19, 2024, highlighting critical details about Politan and Quentin Koffey's plan to take control of Masimo and failure to act in the best interests of all Masimo stockholders. Masimo is urging stockholders to vote "FOR" the Company's director nominees, Joe Kiani and Christopher Chavez, on the updated GOLD proxy card to protect the Company and the value of their investment. Stockholders of record as of the close of business on August 12, 2024 are entitled to vote at the Annual Meeting.

09:18 EDT Procaps Group sees 1H24 adjusted EBITDA $8M-$10M - The company said: "We are exploring various alternatives to obtain additional financing, to bring a sustainable cash position which we believe will allow the Company the necessary flexibility to pursue key initiatives and further invest in higher growth segments with stronger margins, such as prescription pharmaceutical drugs. With the measures above we want to demonstrate that we are focused on reducing our debt burden and improving our EBITDA margins through operational efficiencies, cost control measures, and strategic asset sales where necessary. We expect that our ongoing restructuring efforts will support these goals, allowing us to optimize cash flow and invest in high-growth segments."

09:17 EDT Jakks Pacific extends global rights for Stranger Things, Bridgerton - Disguise announced the extension of its global rights to design and develop costumes based on characters from Netflix's hit series Stranger Things and Bridgerton for fall 2024. The Stranger Things collection includes a range of classic and fan-favorite costumes for both kids and adults, featuring iconic characters such as Eleven, Robin and Steve from Scoops Ahoy, Hellfire Club captain Eddie Munson, Hawkins Cheerleader Chrissy, and extending the Demogorgon into infant and toddler sizing so the full family can dress up. The new Bridgerton line, available this fall, showcases stunning adult costumes inspired by Penelope and Colin Bridgerton and reflects the detail to design that was given to the original versions in the series by Shondaland.

09:17 EDT Procaps CEO says 'working diligently' to complete internal investigation - Procaps Group CEO Jose Antonio Vieira, in a letter to shareholders, said the company is working diligently with its accounting and legal advisors, in cooperation with external auditors, to complete the investigation in a timely manner "so that we can report audited financial statements to our shareholders." Vieira said "I firmly believe in the long-term potential of the business and intend to chart the right path forward for Procaps to realize this value. While I acknowledge the near- and medium-term challenges our business faces, I remain confident, just as I did when I took this job, that Procaps is a viable organization with concrete growth perspectives and a path to profitability. However, this year our primary focus is on addressing our internal challenges. Our future depends on us concluding this investigation process and filing our audited financial statement with our 2023 20-F. In the meantime, we are working to correct the course where needed, securing financing and implementing our strategic plan." The executive noted that the Luxembourg Court has ruled entirely in its favor, dismissing all of Hoche's claims as unfounded. "The Court thoroughly examined the arguments from both sides and disregarded the arguments made by Hoche and upheld all the defenses presented by Procaps," he said.

09:16 EDT 180 Degree Capital notes average discount of NAV per share to stock price - 180 Degree Capital noted that the average discount between its estimated daily net asset value per share and its daily closing stock price during August 2024 and year-to-date through the end of August 2024, were approximately 21% and 19%, respectively. This discount was approximately 25% on August 30, 2024, the last day of trading in the month. As previously disclosed in a press release on November 13, 2023, 180 Degree Capital's Board of Directors has set two measurement periods of January 1, 2024 to December 31, 2024, and 2) January 1, 2025 to June 30, 2025, in which it will evaluate the average discount between TURN's estimated daily NAV and its closing stock price pursuant to a Discount Management Program. Should TURN's common stock trade at an average daily discount to NAV of more than 12% during either of these measurement periods, the Board will consider all available options at the end of each measurement period including, but not limited to, a significant expansion of 180 Degree Capital's current stock buyback program of up to $5 million, cash distributions reflecting a return of capital to shareholders, or a tender offer. We currently believe that any option and amount selected by the Board will be chosen carefully to not jeopardize the long-term potential of TURN to create value by requiring the monetization of a significant portion of TURN's portfolio at historically low stock prices.

09:15 EDT BEN contracts with IntelliTek to broaden AI healthcare - Brand Engagement Network announces a contractual agreement has been reached between BEN, an up-and-coming supplier of safe, customized AI for consumer engagement, and IntelliTek, a SmarTek21 subsidiary that creates solutions for virtual assistants that interact with patients. "This cooperation with BEN will enable both companies to offer a comprehensive suite of AI solutions for the healthcare industry, which is experiencing critical challenges surrounding workforce and resource availability," said Martyn Molnar, CEO, Intellitek Products. "By broadening our customer base with this collaboration, we're also broadening the reach of our solutions to a larger range of healthcare providers and patients - increasing access to life-saving AI "We're proud to have found a likeminded ally in IntelliTek, as we both strive to elevate patient experiences and healthcare professional productivity with innovative AI technology," said Paul Chang, CEO of BEN. "Together, our platforms can serve as an end-to-end suite of solutions that offer round-the-clock, instant support to improve both healthcare access and outcomes."technology."...

09:14 EDT GlucoTrack appoints John Ballantyne to board of directors - Glucotrack announced the appointment of John Ballantyne, PhD to its Board of Directors, effective immediately. Ballantyne brings over 20 years of experience on the executive team at the global biotechnology contract development and manufacturing organization, Aldevron. He co-founded the company in 1998 and served as its Chief Science Officer through its acquisition by Danaher, and until his retirement.

09:13 EDT CarGurus names Mike O??????Hanlon as Chief Revenue Officer - CarGurus announced the appointment of Mike O'Hanlon as Chief Revenue Officer CRO effective September 3, . With deep experience driving customer growth and retention strategies for online marketplace and software as a service SaaS businesses, O'Hanlon will lead CarGurus' Sales and Service teams to support growth objectives and priorities to nurture deeper relationships with dealer partners.

09:13 EDT AGBA Acquisition, Triller announce amended, restated merger agreement - AGBA Group Holding Limited and Triller Corp. announced that on August 30, 2024, the parties amended and restated their April 16, 2024 merger agreement. This amended and restated Merger Agreement supersedes the original merger agreement between AGBA and Triller. In accordance with the Merger Agreement, AGBA will domesticate to the U.S. as a Delaware corporation and all AGBA ordinary shares, par value $0.001 per share, will automatically convert into the same number of shares of AGBA Delaware Parent upon successful AGBA Domestication and Delaware incorporation. Once the Triller Reorganization and the AGBA Domestication have occurred, the combined companies will merge and Triller will become a wholly owned subsidiary of AGBA Delaware Parent. Upon successful closing of the transaction, AGBA Delaware Parent will change its name to "Triller Group Inc." and the newly combined companies will operate under the Triller company name and expect to be traded on the Nasdaq under the ticker "ILLR". The merger consideration provided for in the Merger Agreement will be as follows: AGBA Delaware Parent (i) will issue 299,897,852 shares of AGBA Delaware Parent Common Stock to the current common stockholders of Triller, (ii) will issue 37,702,230 shares of preferred stock to the current preferred stockholders of Triller, and (iii) will convert all existing Triller restricted stock units into 54,020,128 AGBA Delaware Parent restricted stock units; and AGBA Delaware Parent also will reserve an aggregate of 54,020,128 shares of AGBA Delaware Parent Common Stock for future issuance upon the vesting of such restricted stock units. A total of 50,000,000 shares of AGBA Delaware Parent Common Stock will be held in escrow as reserved shares, which will be applied toward future settlement of certain Triller legal and financial obligations. AGBA and Triller have agreed that the closing of the Merger will occur as soon as possible, subject to regulatory clearance, approval by AGBA's shareholders and the other closing conditions provided for in the Merger Agreement.

09:11 EDT Papa John's announces PepsiCo as its beverage partner in North America - Papa John's International (PZZA) announced its selection of PepsiCo (PEP) as its exclusive beverage supplier for restaurants in North America through a 10-year contract renewal. The extension of this partnership showcases the brand's ongoing commitment to deliver exceptional value to its customers and franchise partners by offering quality products that customers expect.

09:11 EDT MP Materials announces $300M increase to its share repurchase program - MP Materials announced that its Board of Directors has approved a $300 million increase to the Company's existing share repurchase program, bringing the total authorized amount to $600 million. The share repurchase program has also been extended and is now effective until August 30, 2026.

09:09 EDT Longeveron announces type C meeting with FDA for Lomecel-B BLA - Longeveron announced the positive Type C meeting with the U.S. Food and Drug Administration , supporting the advancement of Lomecel-B(TM), a proprietary, scalable, allogeneic, investigational cellular therapy currently being evaluated in a Phase 2b clinical trial for hypoplastic left heart syndrome. The Company and the FDA reached foundational alignment on the primary endpoint and secondary endpoints for ELPIS II. The FDA confirmed that, with several conditional requirements to be accomplished, ELPIS II may be deemed pivotal, and, if positive, acceptable for Biological License Application submission for full traditional approval. Among other items, the Company will need to submit its prespecified Statistical Analysis Plan and Chemistry, Manufacturing and Controls readiness plan, including Lomecel-B stability and comparability data, to the FDA for prior review.."We are pleased to have alignment with FDA on the development pathway for our Lomecel-B(TM) development program in HLHS, which has a devastating impact on patients and their families," said Wa'el Hashad, Chief Executive Officer of Longeveron. "While we have a lot of work yet to do, the potential for ELPIS II to serve as the foundation for a BLA submission significantly reduces the time to reach submission and potential approval of Lomecel-B(TM) as an HLHS adjunct therapy.".

09:09 EDT Supermicro doesn't see material changes in Q4 or FY24 results - On September 3, Supermicro disclosed in a regulatory filing a letter issued to its customers and partners, in which Founder, President and CEO Charles Liang wrote: "You may have seen our recent announcement that Supermicro will be delayed in filing its Annual Report for the fiscal year ended June 30, 2024, and separately, a report published by a short seller. I wanted you to hear from me directly about what they mean for you and our products. Neither of these events affects our products or our ability and capacity to deliver the innovative IT solutions that you rely on every day. Our production capabilities are unaffected and continue operating at pace to meet customer demand. Our world class engineering and support teams are also unaffected and continue to build and deploy large scale AI Total Solutions. Our liquid-cooled solutions continue to ramp. We have shipped approximately 2,000 DLC liquid-cooled AI racks to customers, which we believe is more than 75% of the entire DLC liquid-cooled AI server market this calendar year. Ultimately, we remain well-positioned to deliver our broad product portfolio to you and our thousands of other customers around the world. Our primary focus remains to help you meet your IT challenges and execute your mission. In terms of our Annual Report, the Audit Committee of the Board of Directors decided to delay the filing and, as we shared publicly, has also formed a committee to review our internal controls and other matters. The Board committee is working diligently on this thorough review. Importantly, however, when we announced the decision to delay our Annual Report filing, we indicated that based on the work done so far, we don't anticipate any material changes in our fourth quarter or fiscal year 2024 financial results. This is good news. I continue to have strong confidence in our finance and internal teams. Additionally, we remain proud of our strong financial performance driven by our quest to serve your technology needs. We more than doubled revenues year-over-year in fiscal year 2024, which is more than 3 times the industry average, and we are efficiently growing our staff and investing further in innovation to enhance our capabilities. We are becoming stronger year after year. Separately, you may have also heard about a recent report from a short-seller hedge fund that contains false or inaccurate statements about our company including misleading presentations of information that we have previously shared publicly. We will address these statements in due course. As you may know, short seller reports are designed to drive the stock price downwards to serve the short seller's interests to the detriment of the company's shareholders. Your experience as our customer is our number one priority. That experience will not change. We are focused on delivering on our customer commitments and product roadmaps while continuing our robust growth and expansion to meet your evolving needs and support your business objectives. As we look ahead to 2025, we are closing out a historic year with winning products, a record number of orders, a strong and growing backlog of design wins and leading market positions across a number of areas. Your trust in Supermicro drives that success. We are proud to be your partner and grateful for the opportunity to continue and further grow this partnership. Please do not hesitate to reach out to me or your relationship contact at the company with any questions. Thank you." Reference Link

09:08 EDT Piper Sandler adds Chen as managing director - Piper Sandler Companies announces the addition of Jeff Chen as a managing director to its chemicals investment banking team.

09:04 EDT CleanSpark provides August 2024 Bitcoin mining update - CleanSpark released its unaudited bitcoin mining and operations update for August. Bitcoin mined in August: 478; CY2024 bitcoin mined: 4,586; total bitcoin holdings as of August 31: 7,558; total bitcoin sold in August: 2.50; fleet efficiency: 22.70 J/Th; month-end operating hashrate: 22.6 EH/s. The company sold 2.5 bitcoin in August 2024 at an average price of approximately $56,729 per bitcoin. The average hashrate throughout the month of August was 21.3 EH/s resulting in an average of 15.43 bitcoin mined daily and a single day high of 17.88. 15 MW of additional Dalton data center capacity is expected to be energized and fully hashing by next week. 50 MW of additional Sandersville data center capacity is expected to be energized and fully hashing by mid-month. The initial 30 MW immersion-cooled Wyoming facility is progressing as planned. Power agreements for the sites totaling 75 MW of power were executed in July. In Tennessee, the company is currently utilizing approximately 50 MW of infrastructure under a hosting agreement, which will be owned upon completion of the acquisition of GRIID Infrastructure Inc. 80 MW of additional data center capacity is also under construction by GRIID, which will also be owned upon completion of the sites and the closing of the acquisition.

09:01 EDT Jack Henry announces collaboration with Moov - Jack Henry announced a collaboration with Moov, a modern digital payments processor, to enable community and regional financial institutions to offer enhanced digital payment services to small and medium-sized business customers. The cloud-native service will allow SMBs to accept payments with the tap of a phone, receive same-day funds for payments accepted, and automate reconciliations to accounting software packages. The service will be offered through financial institutions, enabling them to more fully serve their business clients' deposit and payments needs.

09:01 EDT First National Corp. and Touchstone announce shareholders approval of mergerFirst National Corp. - At separate shareholder meetings held on August 29, 2024, First National Corporation (FXNC) the bank holding company of First Bank, and Touchstone Bankshares (TSBA), the bank holding company of Touchstone Bank, received the required approval of each company's shareholders to consummate the previously announced merger of Touchstone with and into First National in an all-stock transaction . Immediately following the Merger, Touchstone Bank would then merge with and into First Bank. The parties expect the Merger to be effective in the fourth quarter of 2024

08:58 EDT NewtekOne names Andrew Kaplan as Chief Strategy Officer - NewtekOne has hired Mr. Andrew Kaplan as Chief Strategy Officer, effective September 3. Kaplan comes to NewtekOne with over 35 years of experience in banking and financial services, with the focus on creating and managing diverse business lines such as payments, digital banking, retail banking, premier banking, and marketing. Most recently, Mr. Kaplan was the Chief Digital Officer at Flagstar Bank, where he helped transform a dormant digital brand to a leading digital bank and developed a new vertical for the bank, resulting in multi-billion-dollar deposit growth and a 17x increase in accounts in 24 months, with a comprehensive risk and control framework. Prior to Flagstar Bank, Andrew held multiple senior positions in banking areas where he managed the development and growth of key initiatives in areas such as retail products and services, third-party financial solutions, treasury management services, institutional deposits, and retail branch expansion. Andrew began his career in financial services as an investment broker as well as a senior consultant at Citibank Investment Services.

08:55 EDT Better Choice Company to acquire SRx Health for $125M - Better Choice Company announced signing a definitive agreement to acquire SRx Health Solutions, a provider of innovative healthcare solutions, in an all-stock transaction for approximately $125M. SRx Health operates one of the largest specialty pharmacy networks in Canada with 35 specialty pharmacy locations, 40 specialty health/infusion clinics, 4 clinical trial sites and 2 wholesale distribution facilities2. SRx Health is only one of a few specialty pharma operators in Canada with a network that extends across Canada, making it one of the most accessible providers of specialty healthcare in the country. SRx Health in 2023 generated C$161.5 million in revenue and C$11.4 million in pro forma Adjusted EBITDA. Better Choice will continue to operate its portfolio of established premium and super-premium pet products under the Halo brand. Upon closing, Better Choice will emerge as a leading global health and wellness company by providing products and solutions for families to make better choices. The combined entity will leverage operational synergies including infrastructure and distribution, as well as implement growth strategies across both entities to launch into new verticals and geographies. Under the terms of the arrangement agreement, each share of SRx Health common stock issued and outstanding will be converted into common stock of Better Choice. The exchange ratio for conversion of the SRx common stock into Better Choice common stock will be determined based on the 30-day volume weighed average price of the common stock of Better Choice subject to an aggregate share collar, with any resulting fractional shares to be rounded to the nearest whole share. At the effective time of the acquisition, securityholders of SRx Health will own approximately 85% of the combined company and securityholders of Better Choice will own approximately 15% of the combined company, on a fully diluted basis. As part of the transaction, Better Choice will spin-out 8% of the issued and outstanding capital stock of its subsidiary, Halo, Purely For Pets, Inc., to Better Choice stockholders immediately prior to the effective time of the transaction. The transaction has been approved by the Board of Directors of both companies. The closing of the transaction is subject to customary closing conditions, including the receipt of required stockholder approvals from SRx Health and Better Choice. The transaction is expected to close in the fourth quarter of 2024. The combined company's Board of Directors following the consummation of the transaction will consist of five members including Adesh A. Vora, Pharm. D., as Chairman, Michael Young, Lionel Conacher, Kent Cunningham, and David White. The combined company will be led by Adesh A. Vora, the founder, President, and CEO of SRx Health, as Chief Executive Officer of Better Choice. Mr. Vora brings over 24 years of pharmacy and healthcare experience to SRx and leads the company with both a deep knowledge of and passion for the Canadian healthcare system. Since SRx's inception in 2013, Adesh has successfully grown the company from just one specialty pharmacy into a national, comprehensive healthcare service provider. He proudly serves on the board of directors of the Neighbourhood Pharmacy Association of Canada, and as President of the board of Seva International Charitable Foundation. Adesh holds a Doctor of Pharmacy degree from the University of Illinois and has completed Alumni Programs at Harvard Business School and the Massachusetts Institute of Technology Sloan School of Management. Dave Sohi, CA, CPA, CBV, currently CFO of SRx Health, will be appointed President of Better Choice. Kent Cunningham, current CEO of Better Choice, will be appointed as CEO of the Halo business unit. Nina Martinez will remain in her role as CFO of Better Choice.

08:52 EDT RDE announces Nasdaq ticker symbol change - RDE announced that it will be changing its ticker symbol from "RSTN" to "GIFT". Effective on Wednesday, September 4, 2024, the Company's common shares will trade on the NASDAQ under the new symbol "GIFT". No action is required by existing shareholders with respect to the ticker symbol change. The Company's common stock will continue to be listed on the NASDAQ and the CUSIP will remain unchanged.

08:50 EDT Trio Petroleum reports increases in estimated oil, gas reserves - Trio Petroleum provided an update on estimates of oil and gas reserves and future net cash flows at its South Salinas Project in Monterey County, California. The Company recently filed with the Securities and Exchange Commission a Registration Statement on Form S-1 that included an updated reserve report, effective April 30, 2024 for the Company's assets at the South Salinas Project. The Reserve Report was prepared by an independent third-party engineering firm, KLS Petroleum Consulting LLC. The updated Reserve Report calculated approximately $475 million in estimated discounted net cash flow to the Company from its Probable Undeveloped Reserves of combined Phases 1-3 in the South Salinas Project, which is an increase of approximately $67 million from the Company's earlier reserve report as filed with the SEC. The Reserve Report recognizes Probable Undeveloped Reserves and Possible Undeveloped Reserves for three project development phases, namely existing wells and permitted drilling locations, an additional 12-well drilling program, and the full development of the field over a four year period. The Reserve Report indicates that the Probable Undeveloped Reserves of combined Phases 1-3, net to TPET, are approximately 40 million stock tank barrels of oil and 42 billion cubic feet of gas, or 47 million barrels of oil equivalent, that the associated Undiscounted Net Cash Flow to TPET is approximately $2.1 billion, and that the associated Discounted Net Cash Flow to TPET is approximately $475 million.

08:48 EDT Chevron boosts oil, natural gas recovery at two facilities in Gulf of Mexico - Chevron Corporation announced that it started water injection operations at two projects to boost oil and natural gas recovery at the company's existing Jack/St. Malo and Tahiti facilities in the deepwater U.S. Gulf of Mexico, where Chevron operations produce some of the world's lowest carbon intensity oil and gas.

08:47 EDT Arcturus Therapeutics receives clearance of IND application for ARCT-032 - Arcturus Therapeutics announced that the U.S. Food and Drug Administration, FDA, has issued a "Study May Proceed" notification for the Company's Investigational New Drug, IND, application, ARCT-032, to treat cystic fibrosis. FDA clearance of the ARCT-032 IND application enables the Company to initiate a Phase 2 multiple ascending dose study to evaluate the safety, tolerability and efficacy of ARCT-032 in people with Cystic Fibrosis.

08:46 EDT Vislink names Joseph Lipowski as new Chief Technology Officer - Vislink Technologies announced the appointment of Joseph Lipowski as its new Chief Technology Officer CTO . A renowned RF and wireless expert, Mr. Lipowski brings over two decades of extensive experience leading high-performance technical teams and overcoming complex communication challenges in demanding environments.Mr. Lipowski has a distinguished record of driving groundbreaking projects that have set new standards in the communications industry. Before joining Vislink, he held several key leadership positions where he played a crucial role in advancing RF system design, software development, and digital beamforming technologies. Most recently, he was Co-Founder and Chief Technology Officer at Starry, Inc., a wireless internet service provider and technology developer. Prior to that, he was Co-Founder and Chief Technology Officer at Aereo, Inc., a live video internet streaming service. He has also held senior engineering roles at LoJack, Lucent and Andrew Corporation. Notably, his expertise includes oversight for cost-effective supply chain selection, ensuring that innovative solutions are delivered with precision and efficiency.

08:45 EDT Sidus Space appoints Coffey as Independent Director - Sidus Space announced that its Board of Directors has appointed Lavanson Coffey as an Independent Director, effective August 27, 2024.

08:44 EDT Shift4 Payments teams up with Bar Rescue's John Taffer - Shift4 has partnered with Jon Taffer to support restaurants in need of assistance with the launch of the new SkyTab Rescue Mission contest, featuring $100,000 in prize money. Starting today, restaurant owners can apply to be one of five winners that will each receive a $20,000 business grant, a one-on-one personalized consulting session with Jon Taffer, and a complete SkyTab POS system for their restaurant or bar. Last year, Shift4 & Jon Taffer awarded two Rescue Mission winners in the first iteration of this initiative and are looking to further their support of small businesses with this new and expanded contest.

08:43 EDT DT Cloud Acquisition signs LOI with Shanghai Maius for business combination - DT Cloud Acquisition has entered into a non-binding letter of intent for a business combination with Shanghai Maius Pharmaceutical Technology. Founded in 2015, Shanghai Maius is a biopharmaceutical R&D company focusing on innovative formulations and targeted small-molecule chemical drugs. Its core products include small-molecule chemical drugs and peptide drugs. Under the terms of the LOI, the Company would acquire 100% of Shanghai Maius's outstanding equity and equity equivalents or all of its business, with the deal structure to be determined later by the parties based on further due diligence findings and other considerations. The post-closing combined public company would use a name consistent with the branding of Shanghai Maius. The Company expects to announce additional details regarding the proposed business combination when a definitive agreement is executed, which is expected in the fourth quarter of 2024.

08:42 EDT DZS says laser-focused on conversion of $150M of scheduled backlog - "As Charlie mentioned, during our earnings call later this week we will share in more detail the various changes and enhancements that have occurred since our last earnings call in early 2023," said Misty Kawecki, CFO, DZS. "Our priority throughout the restatement and delayed reporting process has been thoroughness. While we are disappointed with the length of time it took to complete this process, including the cost, this chapter is now behind us. While we will learn from the past, our focus is looking forward. Despite the softness in capital spending by service providers, especially during the 2H 2023 and 1H 2024, we improved profitability with favorable gross margin and optimized our cost structure by 29% year-over-year. We remain laser-focused on the conversion of approximately $150 million of scheduled backlog, converting our numerous active trials to orders, cultivating a robust sales pipeline and converting $75 million of paid inventory to cash."

08:41 EDT Moderna announces MHRA authorized updated COVID-19 vaccine - Moderna announced that the Medicines and Healthcare products Regulatory Agency, MHRA, has authorized its updated COVID-19 vaccine targeting the JN.1 variant of SARS-CoV-2. Following the MHRA decision, doses will be available for eligible groups as part of the NHS autumn vaccination program, which is prioritized for use in people at greatest risk of serious illness from COVID-19. "As the SARS-CoV-2 virus continues to evolve, COVID-19 continues to present a serious health risk. Updated vaccines targeting circulating strains play a vital role in helping to protect those most at risk from severe illness and hospitalization, alleviating strain on the NHS," said Darius Hughes, UK General Manager of Moderna. "With today's approval from the MHRA, we are pleased that our updated COVID-19 vaccine will be available to the UK public, both through the NHS autumn vaccination program, as well as being available to purchase privately for the first time."

08:39 EDT Pasithea Therapeutics appoints Rebecca Brown to Scientific Advisory Board - Pasithea Therapeutics announced that Rebecca Brown, M.D., Ph.D. has been appointed as a member of the Company's Scientific Advisory Board. Dr. Brown is currently Director of the Neurofibromatosis Clinic at The Mount Sinai Hospital and Assistant Professor in the Department of Neurology, Internal Medicine, and Neurosurgery at the institution. Dr. Brown will contribute scientific insights and valuable clinical perspectives to Pasithea's development of PAS-004.

08:38 EDT WTW launches new property facility with Canopius - WTW announced the introduction of a new property facility with Canopius. This exclusive property option, Client Edge Facility, is now available in the market and was developed by a consortium of industry leaders from WTW Corporate Risk and Broking, North America, Canopius US Insurance, Inc., and Verita Capital Solutions. The new facility will be led by Canopius, underwritten on its U.S. Excess & Surplus paper. Client Edge Facility is designed to provide coverage for large and complex risks, along with middle market property risks for shared and layered programs across WTW's U.S. property portfolio. This Canopius-led facility provides additional property capacity with a specialized premium discount. Client Edge Facility enables WTW to efficiently deliver additional property capacity to clients with a limit of up to $25M. In addition, Verita Capital Solutions' extensive capabilities will enable WTW to continue to expand Client Edge Facility with additional property capacity, aligned with expansion into other lines of business. This is an important step to delivering innovative solutions to WTW's clients, with CRB NA steadfast commitment to driving pioneering solutions for clients across all industries and product lines.

08:36 EDT LiveOne, Kartoon Studios to collaborate on custome audio, video channels - Kartoon Studios (TOON) and LiveOne (LVO) announced a new partnership that will bring three dynamic channels of music and video content to audiences of all ages. This collaboration combines both companies' creative expertise and distribution power to deliver tailored entertainment experiences across multiple platforms. The partnership will introduce three distinct channels: 1. Baby Genius: Aimed at children aged 2-8, this channel will offer engaging and entertaining content to stimulate young minds. From animated adventures to sing-along music, Baby Genius is expected to become the ultimate destination for early childhood entertainment. 2. Stan Lee Presents: Targeted at kids and teens aged eight and older, this channel will showcase music related to superhero stories, exciting adventures, and content of the Stan Lee Universe. Stan Lee Presents is expected to captivate a generation ready for action and inspiration. 3. Cartoon Hangover: Designed for teens aged 15 and up, Cartoon Hangover will provide edgy, original content that pushes the boundaries of animation. All your favorite content from the Frederator network will be combined with the hottest music to create a unique music experience. This channel is expected to become the go-to destination for older kids and young adults seeking fresh, innovative entertainment. Kartoon Studios and LiveOne will distribute this custom content using their existing channels and platforms, with the goal of reaching the widest possible audience. This strategic partnership highlights both companies' commitment to delivering high-quality, age-appropriate content that resonates with viewers across various age groups.

08:34 EDT Oryzon Genomics receives additional 'Decision to Grant' communications - Oryzon Genomics has received additional "Decision to grant" communications for important patents relating vafidemstat, Oryzon's LSD1 inhibitor in clinical development for the treatment of psychiatric disorders like borderline personality disorder and schizophrenia. The Australian Patent Office has issued a Decision to grant communication for Oryzon's patent application AU2018309372 entitled "Methods of treating behavior alterations". The allowed claims cover the use of LSD1 inhibitors, including vafidemstat, for the treatment of aggression and social withdrawal. This patent, once granted, will not expire until at least 2038, excluding any potential patent term extensions that may provide additional protection. A decision to grant has also been received in Malaysia. These two new decisions to grant add to the recent decisions to grant in the corresponding patent applications in Europe and Korea. A patent has already been granted in Russia, and patent applications are pending in other relevant markets. In addition, a Decision to grant communication has been issued by the Mexican Patent Office for Oryzon's patent application MX/a/2021/011256 entitled "Methods of treating borderline personality disorder". This patent, once granted, will not expire until at least 2040. A decision to grant has already been received in the corresponding Japanese patent application, and patent applications are pending in other relevant markets.

08:33 EDT TC Biopharm doses five new patients in the ACHIEVE Phase 2b trial in UK - TC BioPharm announces dosing of 5 new patients in the ACHIEVE Phase 2b trial ongoing in the UK. Currently, the trial has successfully dosed 6 patients with their first of 4 possible doses at the higher dose level. Each 5mL dose contains up to 230 million gamma delta T cells, and a patient is expected to receive up to an approximate 1 billion gamma delta T cells over four doses. Five patients have received their second dose, with 2 of these patients having also received their third dose. This correlates with TCBP's step-wise approach to process improvements, as implemented in Q4 2023, and further steps taken to amend the trial protocol in the first quarter of 2024. New patients will continue to be identified, screened, and enrolled into the study.

08:31 EDT SuperCom secures new orders valued at $2.6M from European Governments - SuperCom is pleased to announce that it has secured additional new orders valued at $2.6M from European Governments. The orders are expected to be fulfilled within the next three months.

08:30 EDT Lexicon:INPEFA benefited heart failure patients regardless of diabetes duration - Lexicon Pharmaceuticals announced that a post-hoc analysis of Phase 3 data from the SCORED clinical trial demonstrated that INPEFA or sotagliflozin, reduced the risk of major adverse cardiovascular events or MACE, and heart failure HF events across the spectrum of diabetes duration. Researchers noted that HF patients with longer durations of diabetes derived greater benefit from INPEFA, even controlling for similar baseline HbA1c, yet all patients regardless of diabetes duration benefited from the therapy. These findings were presented August 30th at the European Society of Cardiology ESC Congress 2024 in London, United Kingdom and online. Diabetes duration is a well-established significant risk factor for cardiovascular CV disease and its progression. People with longer diabetes duration have a higher CV disease risk. The objective of this analysis of SCORED, one of two pivotal studies that led to FDA approval of INPEFA for heart failure in May 2023, was to evaluate if diabetes duration modifies the efficacy of INPEFA. The primary endpoint was a composite of CV death, HF hospitalization, and urgent heart failure visit events. Secondary endpoints included MACE: CV death, nonfatal heart attack and nonfatal stroke.

08:28 EDT Keros Therapeutics closes screening for Phase 2 trial of cibotercept - Keros Therapeutics announced that the Company has closed screening for the TROPOS trial, a Phase 2 clinical trial of cibotercept in combination with background therapy in patients with pulmonary arterial hypertension. As a result, Keros expects to complete enrollment by the end of September and present topline data in the second quarter of 2025.

08:26 EDT BiomX to present cinical trial data for BX004 at ERS - BiomX announces the Company will present data from BiomX's Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections. The poster, titled "Novel nebulized phage cocktail in CF patients with chronic P. aeruginosa pulmonary infection: a Ph1b/2a randomized, double-blind, placebo-controlled trial," reports that the Company's phage cocktail, BX004-A, demonstrated favorable safety and notable microbiologic and clinical efficacy in cystic fibrosis patients with chronic P. aeruginosa pulmonary infections, including in patients on standard of care treatment of elexacaftor / tezacaftor / ivacaftor or ETI . The poster will be available on the Company's website following the poster session. "These data, which encapsulate our previously announced Phase 1b/2a study, continue to be encouraging and support our novel approach to treating cystic fibrosis. The European Respiratory Society is an important opportunity to share these results with the European scientific community, and we are grateful to share these positive data," commented Jonathan Solomon, BiomX Chief Executive Officer.

08:23 EDT Uniti Group announces contract award with large hyperscaler - Uniti Group announced a new 20-year contract award from a strategic hyperscale customer in Alabama. As part of this award, Uniti will construct a new long-haul route that will span over 200 route miles when complete, connecting new data centers optimized for Generative AI, and broadening Uniti's reach throughout the state. In order to deliver on the new contract and create significant capacity for future growth, Uniti will build a multi-duct fiber system with several high-count fiber cables between Montgomery and Mobile, AL. This route will create a diverse path between these two markets allowing Uniti's customers to interconnect to other regional and long-haul routes, which connect data centers in other markets. With deep roots in Alabama and a large presence in the City of Mobile, Uniti continues to invest in its fiber network, enhancing connectivity solutions for its enterprise, wholesale and government segments. In addition to finishing construction on a new multi-duct system across Mobile Bay, Uniti was recently awarded "Alabama Middle Mile" grant funding to continue its network growth efforts, strengthening route diversity throughout the state. This contract award was executed in the second quarter and Uniti plans to deliver these fiber routes to its customer in 2025. Over the last several years, Uniti has built almost 4,000 fiber route miles in Alabama, representing over $300 million of capital investment.

08:21 EDT Haleon launches Eroxon gel for erectile dysfunction - Haleon announced that Eroxon, the first-and-only FDA cleared gel available without a prescription for the treatment of erectile dysfunction, is now available for pre-order in the U.S. through Amazon and will be available at most major retailers in October. Eroxon is clinically proven to help men get an erection within 10 minutes. Clinical study results show that Eroxon is safe and effective in men with ED.

08:20 EDT Aeries Technology announces hub in Guadalajara's La Colonia Americana - Aeries Technology announced the opening of its second office in Mexico, located in the prestigious La Colonia Americana area of Guadalajara. This strategic expansion highlights the increasing trend of nearshoring, as U.S. clients seek to leverage the benefits of outsourcing while maintaining proximity and cultural alignment..."Our new office in Guadalajara will enhance our ability to serve U.S. clients by providing high-quality services and the benefits of nearshore operations," said Mario Jimenez, Head of Mexico Operations. "We are excited to leverage the local talent and contribute to the region's economic growth." The strategic location of the new office will facilitate closer collaboration with clients, offering improved communication and faster response times. This expansion reflects Aeries' vision of driving innovation and operational excellence through strategic nearshore operations.

08:18 EDT Caribou Biosciences says FDA grants Fast Track designations to CB-010 - Caribou Biosciences announced that the U.S. Food and Drug Administration granted Fast Track designations to CB-010 for refractory systemic lupus erythematosus and to CB-012 for relapsed or refractory acute myeloid leukemia. CB-010, an allogeneic anti-CD19 CAR-T cell therapy, will be evaluated in the GALLOP Phase 1 clinical trial in patients with lupus nephritis and extrarenal lupus, subcategories of SLE. The GALLOP clinical trial is on track to initiate by year-end 2024. CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy, is being evaluated in the company's ongoing AMpLify Phase 1 clinical trial in patients with r/r AML.

08:17 EDT BioVie announces FDA authorization of IND for Phase 2 trial of bezisterim - BioVie announced that the U.S. Food and Drug Administration has authorized the Company's Investigational New Drug application to evaluate bezisterim for the treatment of neurological symptoms that are associated with long COVID. Receipt of this FDA authorization puts the Company ahead of schedule and on track to receive an additional $12.6 million in grant funding from the U.S. Department of Defense and initiate its Phase 2 trial. The planned Phase 2 study is a randomized, placebo-controlled, multicenter trial in approximately 200 patients to evaluate the safety and tolerability of 3 months of treatment with bezisterim and the potential ability to reduce the neurocognitive symptoms associated with long COVID. The work is supported by the Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, in the amount of $499,200 for the planning phase with the option, if approved, to receive an additional $12.6 million, to initiate a clinical trial once the planning phase has concluded and milestones have been met, through the Peer-Reviewed Medical Research Program under Award No. HT9425-24-1-0113. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Assistant Secretary of Defense for Health Affairs or the Department of Defense.

08:14 EDT Cue Biopharma to present on CUE-401, CUE-100 series at conference - Cue Biopharma announced that members of its management team will deliver two presentations at The Promise of Interleukin-2 Therapy Conference, taking place September 4-7, 2024 in Paris, France. Presentation Title: CUE-401: A Novel IL-2/TGF-beta fusion protein for the induction & expansion of FOXP3+ regulatory T Cells: Dr. Quayle will present preclinical data on our first-in-class bispecific fusion protein, CUE-401, which induces and expands regulatory T cells through the co-delivery of interleukin 2 and transforming growth factor beta and how this approach differentiates from other Treg-directed therapies. Presentation title: Clinical safety and efficacy of TCR-specific engagers that selectively target IL-2 to tumor-specific T cells: Dr. Levisetti will discuss how the company's lead oncology programs CUE-101 and CUE-102, representative of the CUE-100 series of Immuno-STAT biologics, enable selective targeting of the cytokine IL-2 to tumor specific T cells for enhanced efficacy and safety profiles.

08:13 EDT AquaBounty to sell Rollo Bay farm operation - In a regulatory filing, AquaBounty Technologies announced an update on the company's fundraising efforts. "As previously announced, AquaBounty has been exploring a wide range of funding and strategic alternatives to strengthen its balance sheet and increase its cash position. Today, the Company is announcing that it has made the decision to sell its Rollo Bay farm operation. The farm, located on Prince Edward Island in Canada, was purchased by the Company in 2016 and further developed into a broodstock and egg production operation. The Company's investment banker is conducting the sale process, which is expected to be completed before year end," the company stated. David Melbourne, Chief Executive Officer of AquaBounty, said, "We continue to be focused on securing funding for both our near and long-term needs, so that we can return to pursuing our growth strategy. The Rollo Bay farm was purchased and developed to support an expansion plan for five large land-based grow-out farms. Since we will not require the egg output from the Rollo Bay farm in the near to mid-term timeframe, and since we will retain sufficient egg production capacity for our Ohio farm from our hatchery in Bay Fortune, we have determined that the Rollo Bay farm can be sold at this time to resolve the Company's immediate cash requirements, without impacting our long-term strategy. We are also continuing to pursue additional funding and strategic alternatives with the goal of securing our cash requirements in the coming months," concluded Melbourne. Reference Link

08:13 EDT Regenxbio's RGX-121 shows efficacy in Phase 1/2/3 Hunter syndrome trial - Regenxbio announced positive results from the Phase I/II/III CAMPSIITE trial of RGX-121 for the treatment of patients with Mucopolysaccharidosis Type II, also known as Hunter syndrome. The totality of evidence from the CAMPSIITE trial continues to support RGX-121 as the potential first gene therapy and one-time treatment for MPS II. In the U.S. RGX-121 is also on track to be the first treatment that addresses the neurocognitive decline associated with MPS II, with the potential to be the first-line treatment for patients with neuronopathic disease. Patients receiving RGX-121 at the pivotal dose level demonstrated an 85% median reduction of cerebrospinal fluid levels of heparan sulfate D2S6, a key biomarker of brain disease activity, approaching normal levels and sustained for up to two years. Topline results presented earlier this year from the CAMPSIITE trial demonstrated that the pivotal phase of the trial met its primary endpoint with statistical significance. As of January 5, RGX-121 continues to be well tolerated in 25 patients dosed across all phases of the CAMPSIITE trial. Regenxbio is on track to initiate a rolling Biologics License Application submission using the accelerated approval pathway in Q3 using CSF D2S6 as a surrogate endpoint reasonable likely to predict clinical benefit. Approval of the planned BLA could result in receipt of a Priority Review Voucher in 2025.

08:12 EDT Ryan Specialty signs agreement to acquire Property and Casualty MGUs - Ryan Specialty announce it has signed a definitive agreement to acquire the Property and Casualty MGUs owned by Ethos Specialty Insurance from Ascot Group. Ethos P&C was founded in 2017 by Ascot Group and will become a part of the Ryan Specialty Underwriting Managers division of Ryan Specialty. Ethos' Transactional Liability MGU is not included in the transaction and will remain with Ascot. Terms of the transaction were not disclosed. The acquisition is expected to close during September 2024.

08:11 EDT Freshpet appoints Nicki Baty as COO - Freshpet announced Nicki Baty has been appointed COO, effective September 1, 2024. Ms. Baty will report directly to Billy Cyr, CeO. Ms. Baty spent nearly 20 years at Colgate-Palmolive where she most recently served as President and General Manager of Hill's Pet Nutrition U.S. She has deep experience in driving transformative growth initiatives and leading businesses across multiple international markets. Scott Morris built and created Freshpet's original products, brands and marketing model. Continuing in his role as President and Co-Founder, he will be responsible for developing the future of Freshpet's product portfolio, starting from ingredients to a reimagined consumer proposition utilizing next-generation manufacturing technologies. The goal is to provide Freshpet with the next decade of competitive advantage, solidifying its leadership in fresh pet food. He will work closely with Ms. Baty and the commercial team as the co-founder of the business to fortify the Company's future business and growth models. Ms. Baty will have responsibilities consistent with her role as COO. However, until May 10, 2025 her commercial responsibilities will be limited to the Mass, Grocery, and Club channels.

08:09 EDT Esperion secures additional commercial, Medicare formulary coverage for NEXLETOL - Esperion announced that NEXLETOL and NEXLIZET have achieved additional coverage on national and large regional formularies since the U.S. Food and Drug Administration's approval of the expanded indications, increasing total coverage to more than 136 million commercially insured lives and 34 million Medicare lives. Additionally, many payers have accelerated alignment of utilization management criteria since the FDA approval of the expanded indications to the new labels.

08:08 EDT Nice announces new centralized gateway to Government Services - NICE announced its Integrated Front Door to Government Services. The new FedRAMP Integrated Front Door solution addresses a top government initiative, aiming to improve the citizen experience. It leverages generative AI to deliver a voice and digital entry point that determines constituents' intent, authenticates and then enables constituents to self-serve, or seamlessly transfer to a live agent within the correct agency including all the relevant data and content captured by the CXone platform. This enables government agencies to deliver a frictionless citizen experience.

08:07 EDT Interface expands recycling capabilities in Europe - Interface announced continued efforts to develop a circular economy with expanded capabilities at its recycling facility in Scherpenzeel, Netherlands. The Scherpenzeel recycling plant will now use an innovative process to recycle post-consumer carpet tiles that cannot be reused, supporting Interface's commitment to circularity. This will enable the used products to be immediately returned to the production cycle and used to make new carpet tiles for the European market.

08:06 EDT Spar Group to be acquired by Highwire Capital for $2.50 per share - SPAR Group has entered into a definitive agreement to be acquired by Highwire Capital. Under the terms of the agreement, which has been unanimously approved by SPAR Group's Board of Directors, SPAR Group stockholders will receive $2.50 per share in cash, representing a 72% premium over the closing share price on the last trading day before the announcement and a 37.8% premium over SPAR Group's 30-day volume-weighted average share price. Upon approval by SPAR Group's stockholders and completion of the transaction, SPAR Group will become a privately held company, and its stock will no longer be traded on NASDAQ. The transaction is expected to close in the fourth quarter of 2024, subject to the receipt of stockholder approval, regulatory approvals, and the satisfaction of other customary closing conditions. Highwire has obtained a debt financing commitment, the proceeds of which will be sufficient for Highwire to consummate the transaction contemplated by the merger agreement. Simultaneously with the execution of the merger agreement, William H. Bartels, a member of the SPAR Board and holder of approximately 20% of the outstanding shares, entered into a voting agreement and irrevocable proxy with Highwire. As a closing condition, the Company will have balance sheet cash of not less than $14,200,000 as of the closing date including all amounts expected to be received by the Company in connection with the disposition of any of the Company's entities. Following the close of the transaction, SPAR Group will continue to be led by Mike Matacunas, who has been its President and CEO since early 2021.

08:04 EDT Denali Therapeutics plans to file for accelerated approval of tividenofusp alfa - Denali Therapeutics announced the outcome of a recent successful meeting with the Center for Drug Evaluation and Research division of the U.S. Food and Drug Administration providing a path to filing a biologics license application for accelerated approval and subsequent conversion to full approval for tividenofusp alfa for the treatment of MPS II. Agreement was reached that cerebrospinal fluid heparan sulfate is reasonably likely to predict clinical benefit and can be used as a surrogate endpoint to support accelerated approval for tividenofusp alfa in MPS II. Based on discussions with CDER, Denali will include preclinical and clinical data on biomarkers and safety in the BLA for tividenofusp alfa as a treatment of MPS II and intends to submit the BLA under the accelerated approval pathway in early 2025. Denali also announced new interim data from the Phase 1/2 study being presented at the Symposium of the Society for the Study of Inborn Errors of Metabolism taking place September 3-6, 2024, in Porto, Portugal. The presentations include data from additional study participants and longer duration of treatment with tividenofusp alfa as well as new analyses on biomarkers and clinical outcomes. Highlights are summarized as follows: CSF HS: 90% mean reduction in CSF HS from baseline at Week 24 with all participants having normal or near normal levels at Week 24. CSF HS reduction was sustained through Week 104. Urine GAGs: Proportion of participants with normal total urine glycosaminoglycans increased from 5% of participants at baseline to 77% at Week 24, and the effect was sustained through Week 129. Importantly, the majority of patients were on standard of care prior to switching to tividenofusp alfa, without a protocol defined washout period, suggesting additional urine GAG reduction with tividenofusp alfa treatment. Serum NfL: Significant and sustained reduction of serum NfL from baseline with all participants who had reached Week 129 having normal or near normal levels, suggesting a reduction of neuronal injury in participants with MPS II. More rapid NfL reductions were associated with younger age. Clinical Outcomes: Improvement or stabilization in adaptive behavior and cognitive scores, hearing, liver volume, and growth outcomes were observed. Safety: Tividenofusp alfa was generally well tolerated, with a safety profile that continues to support development as a treatment for MPS II.

08:03 EDT Jabil appoints Dastoor to board of directors - Jabil announced that CEO Michael Dastoor has been appointed to the company's Board of Directors. This appointment follows Dastoor's recent promotion to CEO in May 2024.

08:03 EDT Movano reports on FDA meeting on EvieMED Ring application - Movano Health announced that a meeting with the FDA on August 15 resulted in a positive outcome regarding the EvieMED Ring's wellness features and metrics. Following this development, the company will be working with the agency to move forward with the review process. The EvieMED Ring is a wearable device designed to provide medical device functionality and also offer numerous wellness metrics related to sleep, activity and logging of mood, energy and other characteristics. On April 21, Movano Health filed an updated 510(k) clearance application for the EvieMED Ring's pulse oximetry feature. In late June, the FDA review team requested additional information related to the wellness aspects of EvieMED. Movano Health provided a draft response to the FDA's questions on July 10 and requested a meeting with the agency to review the company's response. Separately, Movano Health recently announced that it will begin taking D2C orders again for the Evie Ring on September 17.

07:54 EDT Lucid Diagnostics partnering with Front Line Mobile Health in esophageal cancer - Lucid Diagnostics (LUCD), a cancer prevention medical diagnostics company subsidiary of PAVmed (PAVM), announced the execution of a memorandum of understanding with Front Line Mobile Health, a comprehensive medical care provider for first responders. The MOU focuses on the exploration of co-marketing and collaboration opportunities to promote and expand patient access to Lucid's EsoGuard Esophageal DNA test for the early detection of esophageal precancer, particularly among firefighters. Front Line is a veteran-owned company that specializes in providing comprehensive medical care for first responders, including fire, law enforcement, and emergency medical services.

07:53 EDT Skyward Specialty Insurance, Bishop Street announce joint venture - Bishop Street Underwriters announced a strategic joint venture with Skyward Specialty Insurance Group. Bishop Street is a value-additive acquirer and program incubator, marrying an MGA's established brand equity with best-in-class capabilities, capital, and resources to build a powerful growth platform. With several deals completed and several more expected to close this year, Bishop Street is partnering with entrepreneurs, operators, and underwriters across specialty P&C markets. The joint venture will accelerate Bishop Street's ability to strengthen MGAs and support existing program expansion, new product and program launches, and underwriting team lift-outs with preferred Admitted and E&S capacity. Bishop Street's data-driven, tech-enabled decision making and value creation capabilities, combined with Skyward Specialty's robust underwriting expertise, distinctive advanced technology and analytics capabilities, primary insurance capacity and financial strength, will further enable Bishop Street to address the unique needs of its MGA businesses and entrepreneurial underwriters looking for a turnkey platform.

07:52 EDT Maris-Tech receives patent for forward error correction optimization method - Maris-Tech has been granted a new patent from the United States Patent and Trademark Office for its innovative forward error correction method, which optimizes FEC processes in media communication streaming. The underlying method was invented by Magenya Roshanski, the CTO of Maris-Tech, further contributing to the Company's technological advancements. FEC is a critical technique used to handle errors in data transmission by adding redundant or additional data alongside the original streamed data. Maris-Tech's novel method optimizes this process by leveraging characteristics specific to video streaming, such as varying frame sizes with different potential for errors. This pioneering method significantly reduces the required overhead data while maintaining and improving effective error correction capabilities. The method encodes, segments and packetizes the frames to generate an elementary stream of media packets with variable sizes.

07:50 EDT flyExclusive enters exclusive agreement to provide services to Volato Group - flyExclusive (FLYX) announced that it has entered into an Aircraft Management Services Agreement, AMS, with Volato Group (SOAR), the largest HondaJet operator in the United States. Under the terms of the agreement, the Company will manage flight operations, sales and expenses of Volato's fleet, consisting of 13 fully fractionalized aircraft, 8 leased aircraft and 4 managed aircraft. The goal is to transfer aircraft to the flyExclusive certificate, which will occur over the coming months in coordination with the FAA. The Company will also execute the flights for the Volato customer base of approximately 184 fractional customers and 265 block customers on the Volato certificate, until they are moved over to FLYX agreements, in addition to Volato's retail and wholesale business. This will significantly increase the FLYX direct-to-customer facing business as planned nearly immediately.

07:48 EDT PowerBand Solutions enters strategic advisory agreement with John Wimsatt - PowerBand Solutions has entered into a Strategic Advisory Agreement with John Wimsatt, former CIO at ECN Capital Corp., to act as an advisor to the Board of PowerBand Solutions Inc. The Company has also approved, up to a CAD $10 million non-brokered, private placement of common shares of the Company. In his role as Advisor to the Board, Mr. Wimsatt will primarily be focused on leading the process to identify and secure the formation of additional lease origination funding facilities and advise the Company with respect to negotiations of structure, price, terms and consideration applicable to any potential transaction. He will also provide strategic oversight, diligence and financial advisory services relating to the Company's automotive leasing origination business. The Company is also pleased to announce the Offering, on a non-brokered private placement basis, of up to 200,000,000 common shares of the Company at a price of $0.05 per Common Share for aggregate gross proceeds of up to CAD $10,000,000. The Company also announces that Mr. Wimsatt, along with insiders, management and existing shareholders, have indicated that they will be participating in the Offering. The net proceeds of the Offering will be used to fund growth initiatives, and for general corporate and working capital purposes, including supporting the restart of lease originations. The Company also reserved the right, in its sole discretion, to increase the Offering size by up to $2,000,000 based on market demand.

07:41 EDT H World CFO Jun Zuo to resign, Hui Chen to succeed - H World Group announced that Mr. Jun Zou will resign as CFO of the Company for personal reasons, effective on September 4, 2024. Ms. Hui Chen, the chief compliance officer of the Company, has been appointed as CFO of the Company, effective on September 4, 2024.

07:40 EDT Praxis announces results from EMBOLD study in SCN2A 8A for epilepsies - Praxis Precision Medicines shared positive topline results for its Phase 2, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy or DEE, patients."We are thrilled to see the combination of positive efficacy and tolerability of relutrigine for SCN2A and 8A, where there are no approved treatments. When comparing to the baseline rates, patients in EMBOLD had over 2,000 fewer seizures since the beginning of the study. This kind of remarkable impact keeps us focused on advancing our programs," said Marcio Souza, president and chief executive officer. "Seizure freedom is the ultimate goal for patients, and we were humbled by the progress made with relutrigine during the EMBOLD study with over 30% of patients achieving this life-altering milestone. Most importantly, we are grateful to the patients, families, caregivers and clinicians who participated in the trial." "On behalf of the international SCN2A and SCN8A communities, whose loved ones face severe, life-threatening health challenges due to devastating seizures and the absence of approved treatments, we are optimistic about the initial results from EMBOLD. The achievement of significant reduction in seizures compared to placebo could represent a meaningful improvement in the lives of these children and their families."

07:38 EDT InflaRx presents new preclinical findings for INF904 - InflaRx announced the presentation of preclinical data for the company's novel oral C5aR inhibitor, INF904, at the 2024 European Meeting on Complement in Human Diseases being held in Lubeck, Germany, September 2 - 6, 2024. Members of InflaRx leadership also participated in a satellite symposium highlighting the role of the C5a/C5aR1 axis in driving inflammation and served as the biopharma industry representative on a panel focused on the relevance of targeting C3 and C5. InflaRx also hosted a lunch seminar focused on C5a/C5aR inhibition in human disease with best-in-class compounds. Preclinical pharmacological characterization of INF904, an oral small molecule antagonist to complement 5a receptor: Overall, this study demonstrated that INF904 is a highly selective and potent inhibitor of C5aR1 with promising pharmacokinetic properties, while also exhibiting strong efficacy potential in vivo. Both INF904 and avacopan were evaluated through a series of cell-based, ex vivo, and in vivo assays. In a hamster neutropenia model, INF904 inhibited C5a-induced neutropenia by 96.5% compared to 51.1% for the same dose of avacopan. INF904 also demonstrated a more favorable PK profile with 2- to 5-fold higher exposure than avacopan across all tested animal species. The data also indicated that INF904 is a much weaker inhibitor of CYP3A4/5, with an IC50 value of 62 microM, compared to 1.7 microM for avacopan. CYP3A4/5 enzymes play an important role in the metabolism of a variety of drugs, including glucocorticoids. INF904, a novel oral C5a receptor 1 antagonist, shows promising therapeutic effects in inflammatory disease models: Results from in vitro and in vivo inflammatory disease models indicated that INF904 acts by reducing neutrophil activation. In two in vitro whole blood disease models, INF904 effectively blocked CD11b upregulation on neutrophils in a dose-dependent manner. Further, in three hamster models used to assess INF904's therapeutic effects after oral dosing, significant anti-inflammatory effects were noted, including reduced influx of neutrophils, significant reductions in plasma levels of CREA and BUN, and histological improvements.

07:36 EDT Yatra entered agreement to caquire 100% of Globe All India Services for $15.15M - Yatra Online announced that it has entered into a definitive agreement, through its subsidiary, Yatra Online Limited, to acquire 100% of Globe All India Services Limited, a premier Corporate Travel Services provider for INR 1280 million, ~USD 15.25 million, in cash. Through this acquisition Yatra will gain Globe Travels' portfolio of approximately 360 corporate customers and annual gross bookings of approximately USD 90 million. This strategic acquisition is expected to further solidify Yatra's position as the leader in the corporate travel sector and marks a significant expansion of its corporate customer footprint in India. The transaction is expected to close within three months of the signing of the agreement, subject to certain closing actions and satisfaction of the conditions precedent as specified in the agreement.

07:35 EDT Redwire completes acquisition of Hera Systems - Redwire announced that it has completed its previously announced acquisition of Hera Systems, a spacecraft development company with expertise in specialized missions for national security space customers. The acquisition of Hera Systems expands Redwire's spacecraft portfolio to support specialized national security space missions in geostationary orbit, GEO. "The acquisition of Hera Systems is an exciting and important milestone in Redwire's growth strategy as we move up the value chain within the national security space sector," said Peter Cannito, Chairman and CEO of Redwire. "Our expanded spacecraft portfolio enables us to offer our customers mission-critical capabilities in GEO, an increasingly important domain within today's national security space architectures. We look forward to bringing together our highly complementary solutions as we continue to deliver for our national security customers and advance our goal of becoming a leading provider for proliferated GEO constellations."

07:33 EDT Driven Brands announces the sale of its Canadian distribution business - Driven Brands Holdings announced the sale of its Canadian distribution business, primarily operated under the PH Vitres d'Auto brand, to PGW Auto Glass, a leading North American glass distributor, effective August 31, 2024. Terms of the transaction are not being disclosed.

07:31 EDT ATI announces $700M share repurchase program - ATI announced that its Board of Directors has authorized the repurchase of up to $700M of its outstanding common stock, which the company currently expects will support a multi-year share repurchase program.

07:29 EDT Lithium Ionic appoints David D'Onofrio to board of directors - Lithium Ionic announced the appointment of David D'Onofrio to its Board of Directors, effective immediately. David currently serves as the CFO of PowerOne Capital Markets Limited, a diversified merchant bank specializing in early-stage capital and advisory services for emerging growth companies globally The Company also announces that Juliana Sprott has stepped down from her role as a Director.

07:26 EDT Freight Technologies announces extinguishment of $1.1M of outstanding debt - Freight Technologies has reached an agreement with Freight Opportunities LLC to extinguish $906K of outstanding promissory notes and accumulated interest and the remaining balance of Convertible Notes held on Freight Technologies' June 30, 2024 balance sheet at $220K. Freight Opportunities remains an equity investor in the Company.

07:25 EDT ASP Isotopes completes construction phase of Ytterbium-176 enrichment facility - ASP Isotopes, an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, announced advances in its construction program and the hiring of key staff..."Currently, there exist significant supply-side challenges for many essential radioisotopes used in various oncology treatments. We have received a considerable amount of interest from customers in North America, Europe and Asia for Ytterbium-176 and we look forward to easing supply chains and improving the quality of life of thousands of patients every year", said Paul Mann, ASP Isotopes's Chairman and CEO...The Company is evaluating the potential opportunity to construct an advanced nuclear fuel plant in the United Kingdom, which would likely result in the inward investment of hundreds of millions of dollars from Quantum Leap Energy LLC and its partners and customers. The advanced nuclear fuel plant would likely create hundreds of permanent jobs in the United Kingdom. ASP Isotopes has previously announced that it has entered into two MOUs with U.S.-based Small Modular Reactor SMR companies that contemplate the SMR companies making capital investments into the development of high-assay low-enriched uranium HALEU enrichment facilities. Potential customers, with whom ASP Isotopes has been in discussions, have indicated their requirements of over $37B of HALEU by 2037

07:22 EDT Emergent BioSolutions closes credit facility agreement with Oak Hill - Emergent BioSolutions announced the closing of a new credit facility agreement with Oak Hill Advisors for a term loan of up to $250 million. Emergent used a portion of the proceeds of the New Term Loan to repay all amounts outstanding under the senior term loan facility under the Amended and Restated Credit Agreement, dated October 15, 2018, by and among Emergent, the lenders party thereto from time to time, and Wells Fargo Bank, National Association, as the Administrative Agent which was scheduled to mature in May 2025. The New Term Loan maturity extends up to five years, through August 2029. Excess proceeds from the refinancing will result in additional cash to the balance sheet. Emergent also terminated its obligations under the senior term loan facility and the revolving credit facility under the Prior Credit Agreement. In connection with the execution of the New Term Loan, Emergent issued the lenders warrants to purchase 2.5 million shares of common stock with a strike price at a premium to the volume weighted average price per share for the 30 trading days ending on, but excluding, the 10th business day following the closing date. In addition, subject to certain limitations Emergent agreed to issue the lenders shares of common stock with an aggregate value of $10 million at a price per share equal to the 30-Day VWAP.

07:18 EDT Skye Bioscience names Puneet Arora, MD as Chief Medical Officer - Skye Bioscience announced the appointment of Puneet S. Arora, MD, MS, FACE, as Chief Medical Officer CMO. "We are thrilled to welcome Dr. Puneet Arora as the Chief Medical Officer at Skye at this pivotal moment in our journey, particularly with the initiation of the Phase 2 CBeyond(TM) obesity clinical trial for nimacimab, our differentiated CB1 inhibitor," said Punit Dhillon, Skye's CEO and Chair. "Dr. Arora is well-regarded in the industry, brings extensive experience in designing and executing clinical trials across multiple therapeutic areas, and has significant expertise in metabolic diseases such as obesity. Our purpose is to advance treatments that can significantly improve health outcomes and we look forward to leveraging his medical knowledge and deep understanding of regulatory and clinical development strategies in the metabolic field as we work toward that goal."

07:16 EDT Vaxcyte reports data from study of VAX-31 vaccine candidate in adults 50+ - Vaxcyte announced positive topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the Company's 31-valent pneumococcal conjugate vaccine PCV candidate designed to prevent invasive pneumococcal disease IPD in 1,015 healthy adults aged 50 and older. Based on the strength of the results from this study, the Company has selected VAX-31 to advance to an adult Phase 3 program."We believe the positive safety, tolerability and immunogenicity results from the VAX-31 Phase 1/2 study affirm the potential of our site-specific, carrier-sparing platform to deliver the broadest-spectrum PCVs that provide protection against both currently circulating and historically prevalent strains," said Grant Pickering, Chief Executive Officer and Co-Founder of Vaxcyte. "Based on the strength and clarity of these data, we have selected VAX-31 for the adult indication and plan to initiate the pivotal, non-inferiority Phase 3 study by mid-2025 and announce topline data in 2026. We intend to initiate the remaining VAX-31 Phase 3 studies in 2025 and 2026 and submit a Biologics License Application subject to the results of these studies." "We are exceptionally proud to share these results, which we believe validate VAX-31's potential as a best-in-class pneumococcal vaccine capable of raising the bar for immunogenicity standards," said Jim Wassil, Executive Vice President and Chief Operating Officer of Vaxcyte. "The public health community continues to highlight the need for broader-protection vaccines to prevent IPD, which is associated with high case-fatality rates, antibiotic resistance and meningitis. To address this need, VAX-31 was designed to increase coverage to more than 95% of IPD circulating in adults 50 and older in the United States, with the potential to provide significantly greater coverage relative to today's standard-of-care adult PCVs. We want to extend our sincere gratitude to everyone involved in this program, especially the study participants, trial investigators and sites, and the entire Vaxcyte team."

07:14 EDT Foghorn Therapeutics appoints Anna Rivkin as CBO - Foghorn(R) Therapeutics Inc. (FHTX) announced that Anna Rivkin, Ph.D., will join the company as Chief Business Officer, on September 3, 2024. Dr. Rivkin brings over two decades of expertise in a broad spectrum of complex business transactions across multiple disease areas. Before joining Foghorn, Anna most recently held leadership roles at Bristol Myers Squibb (BMY) where she successfully oversaw strategic transactions across immunology, neuroscience, and cardiovascular disease as the Vice President of Business Development.

07:12 EDT Precision BioSciences receives $13M in proceeds from Imugene note - Precision BioSciences announced maturity of a $13M convertible note from its previously announced strategic transaction with Imugene for azercabtagene zapreleucel in oncology. The proceeds to Precision BioSciences include $9.75 million in cash and $3.25 million in Imugene ordinary shares. "We are pleased that Imugene continues to advance azer-cel toward a pivotal trial in LBCL for patients with significant unmet need," said Michael Amoroso, President and Chief Executive Officer of Precision BioSciences. "This marks one year since our strategic decision to focus our in-house programs exclusively on in vivo gene editing and further bolsters our balance sheet, enabling us to generate Phase 1 clinical data across multiple in vivo gene editing programs starting in the first half of 2025. In the near term, we are focused on progressing our pipeline towards the clinic and remain on track to file applications with multiple global regulatory bodies for PBGENE-HBV for chronic hepatitis B later this year."

07:11 EDT OTC Markets announces incorporation of EDGAR Online's data into Nasdaq Data Link - OTC Markets Group (OTCM) announced that EDGAR Online's SEC and OTC financials data set is now available on Nasdaq Data Link, Nasdaq's (NDAQ) cloud-based data distribution platform. The integration of EDGAR Online's financial data into Nasdaq Data Link provides subscribers with access to the most comprehensive financials data for all SEC and OTC reporting issuers.

07:09 EDT Ryan Specialty signs agreement to acquire certain assets of Geo Underwriting - Ryan Specialty announces that is has signed a definitive agreement to acquire certain assets of the European managing general agent, Geo Underwriting Europe BV, part of The Ardonagh Group. Geo Europe is based in Rotterdam, Netherlands, with operations in Germany and specializes in Financial Lines. Geo Europe will join the Ryan Financial Lines unit within the Ryan Specialty Underwriting Managers division of Ryan Specialty, complementing RFL's European expansion objectives. The acquisition is expected to close during the third quarter of this year.

07:08 EDT Marti Technologies' ride-hailing service reached over 1.3M riders - Marti Technologies announced that as of August 31, 2024, Marti's ride-hailing service has reached over 1,300,000 riders and over 205,000 registered drivers, exceeding the September 30, 2024 targets of over 1,300,000 riders and 190,000 registered drivers. Marti's number of ride-hailing riders grew 18% from June 30, 2024 to August 31, 2024. The number of registered drivers grew 21% during the same time period. The fast growth in both the rider and driver sides of Marti's ride-hailing marketplace demonstrates the strong need for the service across Turkiye. The service intends to provide readily available, safe, and affordable rides for riders, while providing economic opportunities for drivers across the income spectrum.

07:08 EDT GigaCloud board approveds $46M share repurchase program - GigaCloud Technology announced that its board of directors has approved a share repurchase program to repurchase up to $46 million of its Class A ordinary shares over the next 12 months.

07:07 EDT Macau reports August casino revenue up 14.8% to 19.75B patacas - Macau's gaming bureau reported August gross revenue from games of fortune in the region was up 14.8% year-over-year to 19.754B patacas. Publicly traded companies in the Macau gaming space include Las Vegas Sands (LVS), MGM Resorts (MGM), Wynn Resorts (WYNN) and Melco Resorts (MLCO). Reference Link

07:06 EDT Mint Shango JV to acquire membership interests in Cannabist's Florida entity - MINT Cannabis and Shango announced that they have, through a joint venture, Mint Shango JV, entered into a definitive agreement to acquire all membership interests in The Cannabist Company Holdings Inc.'s Florida subsidiary. This acquisition of a dominant operational Florida vertical is anticipated to provide immediate scale for the MINT SHANGO JV in this state through 14 dispensary locations, two cultivation and manufacturing facilities, all inventory, and its MMTC license for total consideration of $5M. As part of the MINT/SHANGO Transaction, the MINT/SHANGO JV will retain its existing indoor cultivation facility, and The Cannabist Company has separately divested its Lakeland facility. Additionally, the MINT SHANGO JV has also entered into an agreement to transfer to The Cannabist Company all of the outstanding equity interests in its existing MMTC license holder which they plan to divest upon close.

07:05 EDT AxoGen reports inducement grant under Nasdaq listing rule - Axogen has granted an equity inducement award on September 3, 2024, to a new non-executive employee under the terms of the Axogen Inc.'s Inducement Equity Incentive Plan. The award was approved by the Compensation Committee of Axogen's Board of Directors in accordance with NASDAQ Listing Rule 5635(c)(4) and was made as a material inducement to the employee's acceptance of employment with Axogen. The award consists of restricted stock units representing 10,000 shares of the Company's common stock. The RSUs are subject to vesting over 4 years, with 50% vesting after the second year and 25% of the total shares granted vesting every year thereafter for the next two years.

07:05 EDT C4 Therapeutics appoints Stephen Fawell to board of directors - C4 Therapeutics (CCCC) announced the continued evolution of its Board of Directors with the appointment of Stephen Fawell, Ph.D. as a director. With this appointment, Malcolm Salter has decided to retire from the Board of Directors after nearly a decade of service. Fawell has nearly 35 years of drug discovery experience spanning oncology, virology and other disease areas to successfully advance multiple investigational new drugs into clinical trials and ultimately achieve regulatory approval. Most recently, he spent more than a decade at AstraZeneca (AZN) as vice president, head of oncology small molecule drug discovery.

07:03 EDT W&T Offshore names George Hittner as General Counsel - W&T Offshore announced the appointment of George Hittner as Executive Vice President, General Counsel and Corporate Secretary, effective September 1. Hittner brings a unique and extensive combination of legal, corporate and legislative experience in both the public and private sectors.

07:03 EDT Cheer Holding releases AI-based Liaozhai Tales classical literature series - Cheer Holding announced the release of the AI-based series themed on Liaozhai Tales, a collection of classical short stories written by Pu Songling in the early Qing dynasty of China. Episodes including "Adventure of Abao", "Legend of Nie Xiaoqian", "The Taoist Priest of Laoshan" and "The Mystery of Raksasas" are now available on platforms such as Tik Tok, Tencent Video, Little Red Book, Kuaishou, and Weibo, with one new episode released every Sunday and Friday.

07:01 EDT Scorpio Tankers sells two vessels, signs new time charter-out agreement - Scorpio Tankers has entered into agreements to sell two vessels and a new time charter-out agreement. The company has recently entered into agreements to sell two 2014 built scrubber fitted MR product tankers, STI San Antonio and STI Texas City, for $42.5M per vessel. These sales are expected to close within Q4. The company has entered into a three-year time charter-out agreement for the 2018 built MR product tanker, STI Jardins, for $29,550 per day. The charterer is an oil major and the time charter is expected to commence within Q3 and Q4.

06:59 EDT Shoals Technologies granted favorable initial ruling in ITC case against Voltage - Shoals Technologies received a favorable legal ruling from the U.S. International Trade Commission - ITC - in its patent infringement complaint against Voltage and related foreign entity. On August 30, an Administrative Law Judge at the ITC issued an initial ruling finding that Voltage violated Section 337 of the Tariff Act of 1930 by importing infringing LYNX trunk bus products into the U.S. In addition, Shoals has also recently been issued two new patents covering Shoals' BLA technology, in addition to the '153 patent that Voltage was found to violate in the ITC case. If upheld by the Commission, the patent infringement ruling will prevent the unlawful imports of photovoltaic connectors that infringe on intellectual property owned by Shoals for improved solar panel array connectors. The target date for completion of the ITC investigation is scheduled for late December, and final resolution following a potential Presidential review in February 2025. Following final disposition of the ITC case, Shoals plans to resume the currently stayed District Court case in the Middle District of North Carolina against Voltage, on the same subject matter, to pursue monetary damages.

06:56 EDT Paysafe CFO Alex Gersh to step down, John Crawford to succeed - Paysafe announced that Alex Gersh is moving into an advisory role to the CEO, effective September 4th, and will step down as CFO. Alex will remain with Paysafe in his new role for an undefined period, but at least through the end of the year. John Crawford joins Paysafe as Alex's successor, effective immediately, and will be based in the company's North American headquarters located in Jacksonville, Florida.

06:53 EDT Protalix announces repayment of outstanding senior secured convertible notes - Protalix BioTherapeutics has repaid in full all of the outstanding principal and interest payable under its 7.50% Senior Secured Convertible Promissory Notes. The repayment of the convertible notes at maturity was financed entirely with available cash.

06:51 EDT Riot Platforms issues letter to Bitfarms shareholders, urges change to board - Riot Platforms (RIOT) issued an open letter to Bitfarms (BITF) shareholders. The letter, in part, is below: "Dear Fellow Bitfarms Shareholders, Riot currently owns approximately 19.9% of Bitfarms, making us Bitfarms' largest shareholder. As we approach the October 29 special meeting of Bitfarms' shareholders, we want to share our perspectives on the recent actions taken by Bitfarms, including changes to its Board of Directors and the proposed acquisition of Stronghold Digital Mining. We also want to provide an update on our campaign to bring urgently needed change to the Bitfarms Board." Reference Link

06:47 EDT Castellum names Drew Merriman as COO - Castellum announces Andrew Merriman's promotion to COO, effective September 1. Merriman fills Castellum's vacancy created by Glen Ives' promotion to CEO on July 1. Merriman co-founded Merrison Technologies, LLC in 2013, where he served as CEO.

06:36 EDT NextEra Energy, NextEra Energy Partners to meet with investors in September - NextEra Energy (NEE) and NextEra Energy Partners (NEP) announced that members of the senior management team will participate in various investor meetings throughout September. They plan to discuss, among other things, long- term growth-rate expectations for NextEra Energy and NextEra Energy Partners, reaffirming those presented on the July 24, 2024, second-quarter financial results call.

06:35 EDT Central Pacific Bank names Ralph Mesick as Chief Risk Officer - Ralph Mesick has joined Central Pacific Bank as its Senior Executive Vice President and Chief Risk Officer, according to an announcement by Arnold Martines, CPB chairman, president, and CEO.

06:32 EDT G Mining Ventures declares commercial production at Tocantinzinho - G Mining Ventures has reached commercial production on time and on budget at its 100%-owned Tocantinzinho Gold Mine located in the State of Para, Brazil. Commercial production is defined as a period of 30 consecutive days of operations during which the mill operated at a minimum of 60% of nameplate throughput of 12,890 tonnes per day. During August 2024, the mill operated at 76% of nameplate throughput, processing a total of 304,312 ore tonnes at a recovery rate of 88%. The plant's ramp-up continues to progress in line with internal production schedules, with all major equipment demonstrating the capability to operate at or above design levels. After the initial pour announced in July 2024, GMIN has focused on ramping production to test the processing circuits' ability to handle nameplate loads while improving recovery toward a life of mine average of 90%. The Corporation plans to ramp up production through H2-24, targeting nameplate throughput by Q1 2025. TZ is engineered to have a 10.5-year mine life with an average annual gold production of 174,700 ounces and 196,200 ounces for the first five full years, capitalizing on the record-high gold price environment. The Corporation plans to provide annual guidance for TZ in January 2025.

06:31 EDT KalVista announces FDA approval of NDA for sebetralstat - KalVista Pharmaceuticals announced that the U.S. FDA has accepted its New Drug Application for sebetralstat, a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema attacks in adult and pediatric patients aged 12 years and older. The FDA has set a Prescription Drug User Fee Act goal date of June 17, 2025. If approved, sebetralstat would be the first oral, on-demand treatment for HAE in adult and pediatric patients aged 12 years and older. The FDA is not currently planning to hold an advisory committee meeting to discuss the application.

06:21 EDT Grifols postpones Capital Markets Day until further notice - Grifols announced the postponement until further notice of its previously scheduled Capital Markets Day for October 10, 2024. "The Grifols Board of Directors made the decision in light of the potential delisting offer for Grifols' shares being evaluated by Brookfield Capital Partners and certain major shareholders of Grifols linked to the company's founding family. Currently, the Potential Offerors are in process of performing due diligence. At this time, there is no offer, agreement, or decision regarding the potential transaction or its related terms and conditions, nor is there any guarantee or commitment that an offer for Grifols' shares will be made. The Grifols Board and management team are committed to acting in the best interest of all shareholders and remain focused on continuing to execute and deliver Grifols' strategy. Any further update will be communicated to the market in due course and in accordance with applicable laws and regulations," the company stated.

06:09 EDT Iridium unveils Iridium Certus GMDSS - Iridium Communications unveiled Iridium Certus GMDSS, a generational advancement in maritime safety, compliance, and communication. Building on the powerful capabilities of Iridium Certus technology, Iridium Certus GMDSS features distress alert, safety voice and Maritime Safety Information, while integrating additional regulated services like Long Range Identification and Tracking and Ship Security Alert System. The combination of capabilities offered by Iridium Certus GMDSS terminals sets a new standard for the cost, efficiency, and performance of maritime safety and security solutions, making it the critical connectivity service needed for any ship's hybrid network system.

06:06 EDT Ensign Group acquires seven skilled nursing facilities in Colorado - The Ensign Group announced that it acquired the operations of the following skilled nursing facilities in Colorado: Desert Willow Health and Rehabilitation Center, a 106-bed skilled nursing facility located in Pueblo, Colorado; Junction Creek Health and Rehabilitation Center, a 133-bed skilled nursing facility located in Durango, Colorado; Pelican Pointe Health and Rehabilitation Center, a 104-bed skilled nursing facility located in Windsor, Colorado; Riverbend Health and Rehabilitation Center, a 100-bed skilled nursing facility located in Loveland, Colorado; Broadview Health and Rehabilitation Center, a 100-bed skilled nursing facility located in Greeley, Colorado; Westlake Lodge Health and Rehabilitation Center, a 107-bed skilled nursing facility located in Greeley, Colorado; and Linden Place Health and Rehabilitation Center, a 110-bed skilled nursing facility located in Longmont, Colorado. These acquisitions were effective as of September 1, 2024, and are subject to long-term, triple net leases.

06:05 EDT EU says Court of Justice judgment annuls decision to probe Illumina deal - European Commission Executive Vice-President Margrethe Vestager commented on the Court of Justice judgment on the Illumina/GRAIL merger jurisdiction decisions, saying: "Today's judgment by the Court of Justice annuls the Commission's decisions to examine the proposed acquisition of GRAIL by Illumina. In those decisions, the Commission accepted requests by Belgium, France, Greece, Iceland, the Netherlands and Norway to review the transaction pursuant to Article 22(3) of the Merger Regulation. We will carefully study the judgment and its implications... Going forward, in compliance with today's judgment, the Commission will continue to accept referrals made under Article 22 of the Merger Regulation by Member States that have jurisdiction over a concentration under their national rules where the applicable legal requirements are met. In the last few years, several Member States have introduced provisions allowing them to request the notification of transactions that do not meet national thresholds, in situations where they might have a significant competitive impact. The possibilities for referrals to the Commission under Article 22, in compliance with today's judgment, are thus already more extensive than they were at the time of the Illumina/GRAIL referral. More generally, we will consider the next steps to ensure that the Commission is able to review those few cases where a deal would have an impact in Europe but does not otherwise meet the EU notification thresholds." Reference Link

06:05 EDT Tuniu enters strategic cooperation with Tourism Authority of Thailand - Tuniu Corporation announced that the Tourism Authority of Thailand and the Company have signed a Letter of Intent at the TAT head office in Bangkok on August 30, 2024. Ms. Thapanee Kiatphaibool, TAT Governor, signed the agreement with Mr. Donald Yu, Tuniu's founder, Chairman and Chief Executive Officer, in the presence of Ms. Chang Yumeng, Counsellor for Cultural Affairs of the Embassy of the People's Republic of China to Thailand. Thailand has always been one of the most popular overseas destinations for Chinese tourists. From January to July of this year, the number of trips of Tuniu's packaged tours to Thailand increased more than 160% year-over-year. The signing of LOI marks a significant step forward for TAT and Tuniu in strengthening partnership, and includes greater collaboration between the two parties in promotion and communication to enhance the overall travel experience for Chinese tourists in Thailand.

06:03 EDT High Tide to launch next-gen Canna Cabana 2.0 website - High Tide will re-launch the website of its flagship Canadian bricks-and-mortar retail brand, Canna Cabana, which represents more than 90 per cent of the Company's revenue. The new website features the latest tech, resulting in an enhanced user interface and overall improved customer experience, which also includes: New, sleek and modern design; Simplified age verification process; Faster loading times; Enhanced search function with multiple filters; Real-time inventory visibility; Improved search engine optimization; Displays nearby availability for out-of-stock products; Wish list function; Improved live-chat function

06:02 EDT KBR completes LinQuest acquisition - KBR has completed the acquisition of LinQuest Corporation, a provider of advanced engineering, data analytics and digital integration with a strong history of solving complex technical challenges for national security space missions. The acquisition strengthens KBR's capabilities across space, air dominance and connected battlespace missions. LinQuest also has a heritage of serving important U.S. government customers including the U.S. Space Force, U.S. Air Force and other U.S. Department of Defense and intelligence agencies. KBR will immediately begin integrating LinQuest into KBR's Government Solutions segment and Defense and Intel business unit. Given the closing date, LinQuest's financial results are not expected to be material to KBR's Q3 2024 financial results. Therefore, impacts of the acquisition to KBR's full year guidance will be discussed on the Q3 earnings call.

05:57 EDT Nokia announces collaboration with Ruckus Networks - Nokia (NOK)_announced a collaboration with Ruckus Networks, a CommScope business (COMM), to create an innovative solution for deploying seamless in-building and campus-wide connectivity, uniquely tailored to the needs of diverse industry verticals. This partnership offers an integrated fiber and Wi-Fi solution for delivering broadband service inside MDUs, offices, large venues, hospitality, medical facilities, and other enterprise segments. This joint solution combines Nokia's best-in-class fiber-based Optical LAN with Ruckus Network's industry-leading enterprise Wi-Fi and switching solutions, creating an integrated infrastructure.